Form l	PTO-			nent of Cor		Application Number	09/460,216	
		Patent a	and T	rademark	Office	Filing Date	December 13, 1999	
						First Named Inventor	Graham P. Allawa	y et al.
		TION DISCLOSURE STA	TEM		.\	Art Unit	1648	
(Use se	veral	sheets if necessary)		•	馥	Examiner Name	Jeffrey S. Parkin	
<u> </u>				HOO Z O LOO		Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD	
<u></u>		1		ATENT DO	777	ITS		
Examine Initials	-	Number-Kind Code ^{2 (If known)}	MN	M-DD-YYYY		ime of Patentee or Appl	licant of Cited Docum	nent
		U.S. 6,025,154		10-2004	1	i et al.		
01		U.S. 6,265,184	07-	24-2001	P.W.	Gray et al.		
		U.S. 6,268,477	07-	31-2002	P.W.	Gray et al.		
		U.S. 6,488,375	1	10-2002		amson et al.		
		U.S. 6,511,826			L.	i et al.		
		U.S. 6,692,938	02-	17-2004	M. S	amson et al.		
		U.S. 6,743,594	1			i et al.		
		U.S. 6,972,126	<u> </u>		1	Allaway et a	1.	
		U.S. 6,800,447				amson et al.		
		U.S. 6,800,729	10-	05-2004	Y. L	i et al.		
		U.S. 5,449,608	09-	12-1995	N. Y	oung et al.		
	<u> </u>	U.S. 6,261,763 B1	.1			Allaway et al	Ι.	
	<u> </u>	U.S. 6,528,625	03-	04-2003	L. W	ı et al.		
		U.S. 6,930,174	08-	16-2005	M. S	amson et al.		
		U.S. 6,100,087	08-	08-2000	J. Ro	ossi et al.		
		U.S. 5,939,320	08-:	17-1999	D. L:	ittman et al.		
		บ.S. 6,258,527	07-3	10-2001	D. L:	ittman et al.		
+		U.S. 6,258,782	07-1	10-2001	S. Ba	arney et al.		
		FO	DEICN	N PATENT D	OCIDA	ENTRO		
Examiner Initials	Cite No.1	Foreign Patent Document Country Code Number Kind Code		Publication MM-DD-Y	Date	Name of Patentee or Docum		T ⁶
X		WO 92/01451		02-06-1	192			+-
()		WO 95/16789		06-22-1				+
7	1	WO 97/28258		08-22-1				+-
		WO 97/44462		11-27-19				-
		WO 98/18826		05-07-19				†
-		WO 01/55439						\dot{T}
XAMINEI	***************************************	MO 01/33439		08-02-20 DATE CONSID		11/2		<u> </u>
IGNATUR	E /	+				11/12/2001		
EXAMIN	ER: Ihid	al if clation considered, whether or not	citation	is in conformane	c with MI	EP 609: Draw line through	citation if not in conform	nanue

*EXAMINER: shitial if elation considered, whether or not citation is in conformance with MPEP 649: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English Language Translation is attached.

Applicants: G.P. Allaway, et al. Serial No.: 09/460,216

Filed: December 13, 1999 Exhibit A

				()			(·)	Page 2 of 19
Form	PT	0-1	449	U.S. Dep	artment of Con	merce	Application Number	09/460,216
					nd Trademark (Filing Date	December 13, 1999
							First Named Inventor	Graham P. Allaway et al.
INFO	RM	IAT	ION DISCLOSU	RE STA	FEMENT		Art Unit	1648
(Use :	seve	ral :	sheets if necessary	/)			Examiner Name	Jeffrey S. Parkin
							Attorney Docket No.	50875-F-PCT US/JPW/AG/LAD
				•	U.S. PATENT DO	CUMENT	rs	
Exami		Cite No.1	Document Nun Number-Kind Code		Publication Date MM-DD-YYYY	Nar	ne of Patentee or Appl	icant of Cited Document
م	П		บ.s. 6,692,9	38	02-17-2004	M. Sa	mson et al.	
Y	1		บ.S. 5,071,9	64 .	12-10-1991	M. Du	stin et al.	
			U.S. 5,091,5	13	02-25-1992	J. Hu	ston et al.	
			U.S. 5,215,9		L		Posner et al	
			U.S. 5,225,5	39			Winter et al	•
T			U.S. 5,603,9	33	02-18-1997	V.A.	Dwyer et al.	
			U.S. 5,668,1	49	09-16-1997	S. Or	oszlan et al	•
			U.S. 5,817,7	67	10-06-1998	G.P.	Allaway et a	1.
			U.S. 5,854,40	00	12-29-1988	T. Ch	ang et al.	
			U.S. 4,886,7	43	12-12-1989	L.E.	Hood et al.	
			U.S. 2003/00	23044	01-30-2003	Y. Li	et al.	
			U.S. 2005/02		11-24-2005	P.W.	Gray et al.	
			U.S. 2005/01	18677	06-02-2005	P.W.	Gray et al.	

FOREIGN PATENT DOCUMENTS

L. Wu et al.

C. Combadiere et al.

C. Combadiere et al.

D. Littman et al.

L. Lopalco et al.

09-04-2003

12-23-2004

10-16-2003

05-22-2003

01-02-2003

U.S. 2003/0166870

U.S. 2004/0259785

U.S. 2003/0195348

U.S. 2003/0096221

U.S. 2003/0003440

Examiner Initials	Cite No.1	Foreign Patent Document Country Code ^t Number th Kind Code ^{f (Flamon)}	Publication Date MM-DD-YYYY	N	lame of P	atentee or Applicant of Cited Document	T ⁶
X		WO 02/064612	08-22-2002				
U _I		WO 01/58915	08-16-2001			•	
		WO 01/58916	08-16-2001				
		WO 96/39437	12-12-1996				
		WO 97/22698	06-26-1997				
		WO 97/44055	11-27-1997				
7		wo 97/032019	09-04-1997		1	1	
EXAMINER SIGNATUR		A	DATE CONSIDERED	h	12	2007	

*EXAMINER: Initial is citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Mind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

09/460.216 Form PTO-1449 **Department of Commerce** Application Number Filing Date December 13, 1999 **Patent and Trademark Office** First Named Inventor Graham P. Allaway et al. Art Unit 1648 INFORMATION DISCLOSURE STATEMENT Examiner Name Jeffrey S. Parkin (Use several sheets if necessary) Attorney Docket No. 50875-F-PCT US/JPW/AG/LAD U.S. PATENT DOCUMENTS Examiner Cite Document Number **Publication Date** Name of Patentee or Applicant of Cited Document Number-Kind Code (if known) hitials No. MM-DD-YYYY U.S. 2002/0150888 10-17-2002 P.W. Gray et al. U.S. 2004/0161739 08-19-2004 M. Samson et al. U.S. 2004/0230037 11-18-2004 P.W. Gray et al. U.S. 2004/0110127 06-10-2004 Samson et al. U.S. 2005/0154193 07-14-2005 Roschke et al. U.S. 2003/0100058 05-29-2003 Roschke et al. U.S. 2003/0166024 09-04-2003 Rosen et al. U.S. 2004/0151719 08-08-2004 Li et al. U.S. 2001/0000241 04-12-2002 Li et al. U.S. 2001/0046512 11-29-2001 V.M. Litwin et al. U.S. 2002/0048786 04-25-2002 Rosen et al. U.S. 2002/0061834 05-23-2002 Rosen et al. U.S. 2002/0110870 08-15-2002 Samson et al.

U.S. 2003/0023044

U.S. 2006/0029932

U.S. 2006/0140977

2002/0045161

2004/0062767

U.S.

U.S.

SIGNATURE

FOREIGN PATENT DOCUMENTS

W.C.

Li et al.

G.P. Allaway et al.

G.P. Allaway et al.

G.P. Allaway et al.

Olson et al.

01-30-2003

02-09-2006

6-29-2006

04-18-2002

04-01-2004

Examiner Initials	Cite No.1	Foreign Patent Docume Country Code Number Kind Cod	nt Publication Date MM-DD-YYYY	Nam		or Applicant of Cited ocument	T ⁶
X		EP 9687002.1	03-01-1996			·····	
U,		EP 96870102.9	08-06-1996			· · · · · · · · · · · · · · · · · · ·	1
		EP 1145721 A2	10-17-2001				
		EP 1146055 A2	10-17-2001				_
		EP 1146122 A2	10-17-2001				1
		EP 1148126 A2	10-24-2001				1
4		EP 1148127 A2	10-24-2001	1	L		1
EXAMINE	}	7	DATE CONSIDERED			<u></u>	

*EXAMINER: Initial if chation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

Form PTO-1449		449 U.S. Depa	artm	ent of Com	merce	App	licution	Number	09/460,216	
		Patent an	d T	rademark C	ffice	Filing Date December 13, 1999			999	
		·				Firs	Named	Inventor	Grabam P. Alla	P. Allaway et al.
INFOR	MAT	ION DISCLOSURE STAT	ΈM	ENT		Λπ	Unit	• • • • • • • • • • • • • • • • • • • •	1648	
(Use sev	eral	sheets if necessary)				Exa	miner N	ame	Jeffrey S. Parki	n
		•				Atto	rney Do	cket No.	50875-F-PCT	
		[LS. P	ATENT DOC	LIMEN	 PS			US/JPW/AG/LA	ND
Examiner Initials	Cite No.	Document Number Number-Kind Code ^{2 (M known)}	Puh	lication Date			Patent	e or Appl	icant of Cited Do	cument
		•								
			-							
								··		
										
		·								
					<u></u>					
										
		<u> </u>		1						
		FOR	<u>EIGI</u>	PATENT DO	CUME	NTS	3			
Examiner Initials	Cite No.1	Foreign Patent Document Country Code Number Kind Code (**)	ha-m)	Publication MM-DD-YY		N	ame of I	atentee or Docur	Applicant of Cited nent	T ⁶
\mathcal{N}		EP 1149582 A2		10-31-20	01					
U_{1}		EP 1199360 A2		04-24-20	02					
		EP 1482042 A1		12-01-20						
		EP 0815137		12-12-19						
		EP 0883687 B1		11-27-20					<u>-</u>	
4 7		CA 2216990		12-27-19		-		<u> </u>		
EXAMINER SIGNATURI				DATE CONSIDI	ERED	u	12	200)	
and not consi of Codes of I	idered JSPT	all of citation considered, whether or not conclude copy of this form with next community attent Documents at www.uspto.gov or the indication of the protect documents.	unicat MPEP	ion to applicant. ¹ 901.04. ³ Enter O	Applicant ffice that i	EP 6 s uni ssued	que citati the docu	on designati	on number (ontional)	Kinds w

ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English Language Translation is attached.

		L.J	F. 3	rage J OL 1.
Form PT	O-14 4	9 U.S. Department of Commerce	Application Number	09/460,216
		Patent and Trademark Office	Filing Date	December 13, 1999
				Graham P. Allaway et al.
		ON DISCLOSURE CITATION	Art Unit	1648
(Use sever:	al sheet	s if necessary)	Examiner Name	Jeffrey S. Parkin
				50875-F-PCT
				US/JPW/AG/LAD
		NON PATENT LITERATURE	DOCUMENTS	
Examiner Initials	Cite No.	include name of the author (in CAPITAL LETTERS), titl item (book, magazine, journal, serial, symposium, catalog	g, etc.) date, page(s), volum	ropriate), title of the ne-issue number(s),
		publisher, city and/or country Abaza, M.S.I et al., (1992)		3-1 3-13
1/		Substitutions Outside An Antigenic	"Effects Of Site On Protei	Amino Acid
$X \mid$		Monoclonal Antibodies Of Predeterm	ined Specificity	Obtained By
		Peptide Immunization: Demonstr	ation With Re	gion 94-100
- -		(Antigenic Site 3) Of Myoglobin",	J. Prot. Chem.	11(5):433-443
, ,		Alexander, H. et al., (1992) "Al Proteins", Proc. Natl. Acad. Sci.	tering The Ant	igenicity Of
1				
1 1		Retroviruses	act At 3rd Co	onierence On
_		Allan, J., (1997) "Human Immu	nodeficiency V	irus-Related
1 1		Infections In Animal Model Syst	ems", In AIDS	: Biology.
1 1		Diagnosis, Treatment And Preventio	n, 4th Edition.	Lippincott-
		Raven Publishers, Philadelphia, Pp	15-27	
1 1		Allaway, G.P. et al., (1993) "Syne Envelope-Mediated Cell Fusion B	rgistic Inhibit	ion Of HIV-1
1 1		Combination With Antibodies To gp	y CD4-Based M 120 Or cm41*	olecules In
		Retroviruses 9:581-587	120 Or gpar , A	TIDS KES RUII
		Allaway, G.P. et al., (1995) "Expr	ession And Char	acterization
		Of CD4-IgG, A Novel Heterotetramer	That Neutralizes	Primary HIV
		Type 1 Isolates", AIDS Res Hum Ret. Amara, A. et al., (1997) "HIV Co	rovirus 11:533-	539
- 1 1		Antiviral Principle: SDF-lα-Depend	lent Internaliza	egulation As
		Chemokine Receptor CXCR4 Contribu	ites To Inhibi	tion Of HIV
		Replication", $J.$ Exp. Med. $186:139.$	-146	
•		Arthos, J. et al., (1989) "Identif	ication Of The	Residues In
		Human CD4 Critical For The Binding	of Hiv. Cell	57:469-481
		Ashorn, P.A. et al., (1990) "Hur	man Immunodefic	iency Virus
		Envelope Glycoprotein/CD4 Mediated	Fusion Of Nonp	rimate Cells
		With Human Cells", J. Virol. 64:214 Attanasio, R. et al., (1991) "Anti-	19-2156	-3.5
1 1		To Monoclonal Anti-CD4 Preparat:	ions In Norbu	ody Kesponse
		Species", J. Immunol. 146:507-514		i .
		Baba, M. et al., (1988) "Mechanis	m Of Inhibitor	y Effect Of
		Dextran Sulfate And Heparin C	n Replication	Of Human
		Immunodeficiency Virus <i>In Vitro",</i> 85:6132-6136	Proc. Natl.	Acad. Sci.
		Baulerle, P.A. And Huttner, W.B., (1987) "Tyrosine	Sulfation Isl
	ŀ	A Trans-Golgi-Specific Protein M	odification",	Cell. Biol.
+		105:2655-2663		•
4	į.	Benet et al. (1990) "Pharmacokinet	ics: The Dynam	nics Of Drug
Y.	į,	Absorption, Distribution And Eli Gilman's The Pharmacological Basis	mination" In (Goodman And
		El., Eds. Pergamon Press, New York,	Pp. 3-32	s, Gliman Et
XAMINER	1	DATE CONSIDERED		
IGNATURI		DATE CONSIDERED III	2/2007	
EXAMINER:	: Initial/If	cilation considered, whether or not citation is in conformance with		citation if not in conformance

*EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

Form PI	ro-144	9 U.S. Department of Commerce	Application Number	09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
			First Named Inventor	Graham P. Allaway et	al.
INFORM	MATIC	ON DISCLOSURE CITATION	Art Unit	1648	
		s if necessary)	Examiner Name	Jeffrey S. Parkin	
			Attorney Docket No.	50875-F-PCT	
				US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catal publisher, city and/or countr	og, etc.) date, page(s), volur	ropriate), title of the ne-issue number(s),	T ²
λ		Berger, E.A. et al (1996) Abst Symposium	ract No. 002, 8	At Keystone	
7		Berger, E.A., (1997) "HIV Entry Receptor Connection" AIDS 11(Supp.		he Chemokine	
		Berger, E.A. et al., (1999) "Ch Coreceptors: Roles In Viral Entry Rev. Immunol. 17:657-700	nemokine Receptor, Tropism And D	rs As HIV-1 isease", Ann.	
		Bieniasz, P.D. et al., (1997) "H Mediated By Multiple Regions Withi The CCR5 Co-Receptor", EMBO 16:25	n Both The Viral	ll Fusion Is Envelope And	
	The CCR5 Co-Receptor", EMBO 16:2599-2609 Blanpain, C. et al., (1999) "Multiple Charged And Aromatic Residues In CCR5 Amino-Terminal Domain Are Involved In High Affinity Binding Of Both Chemokines And HIV-1 Env Protein", J.				
	Biol. Chem. 274:34719-34727 Brelot, A. et al., (1997) "Role Of The First And Third Extracellular Domains Of CXCR4 In Human Immunodeficiency Virus Coreceptor Activity", J. Virol. 71:4744-4751				
		Broder, C.C. et al., (1993) "The Glycoprotein-Mediated Membrane Expressing Human CD4 Can Be (Component(s)", Virol. 193:483-491	Fusion In Ar Overcome By A	nimal Cells Human Cell	
		Burkly, L. et al., (1995) "Syner Immunodeficiency Virus Type 1 Env Cell Fusion And Infection By An A Combination With Anti-gp-120 Antil 4273	velope Glycoprot Antibody To CD4	ein-Mediated Domain 2 In	
		Burton, D.R. et al., (1994) "Primary Isolates Of HIV-1 By A R Antibody", Science 266:1024-1027	ecombinant Huma	n Monoclonal	
		Busso, M. et al., (1991) "HIV-I Requires The Formation Of Conjugate Uninfected T-Cells In Vitro", AII	es Between Virus- OS 5:1425-1432	-Infected And	
		Camerini, D. et al., (1990) "A CD Mediated Syncytium Formation Lies Site", Cell 60:747-754	4 Domain Import Outside The V	irus Binding	
		Cammack, N., (1999) "Human Immunod And Chemokine Receptors: A New Th Chem. Chemother. 10:53-62	erapeutic Targe	t", Antivir.	
1		Capon, D.J. et al., (1989) "Desigr AIDS Therapy", Nature 337:525-531	ning CD4 Immunoa	dhesions For	
XAMINEI IGNATUR		DATE CONSIDERED	12 2007		
nd not consid	lered. Incl	ficiation considered, whether or not citation is in conformance with old copy of this form with next communication to applicant. Appli	n MPEP 609: Draw line throug icant's unique citation designal	h citation if not in conformancion number (optional). ² Applic	æ cunt

is to place a checkmark here if English language Translation is attached.

orm PT	O-14 4		Application Number	09/460,216			
		Patent and Trademark Office	Filing Date	December 13, 1999			
	' 			Graham P. Allaway et :			
		ON DISCLOSURE CITATION	Art Unit	1648			
Jse severa	ıl sheet	s if necessary)	Examiner Name	Jeffrey S. Parkin			
				50875-F-PCT			
		······································		US/JPW/AG/LAD			
		NON PATENT LITERATURE	DOCUMENTS				
xaminer Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), (it item (book, magazine, journal, serial, symposium, catalo publisher, city and/or country	g, etc.) date, page(s), volum	ropriate), title of the ne-issue number(s),			
		Chams, V. et al., (1992) "Simple As	say To Screen F	or Inhibitors			
\ \ \	^	Of Interaction Between The Hun	man Immunodefic	iency Virus			
Y		Envelope Glycoprotein And Its	Cellular Rece	ptor, CD4",			
\cup		Antimicrob Agents Chemother. 36(2) Chan, D.C. et al., (1998) "Evidenc					
i		The Coiled Coil Of HIV Type 1	e That A Promine	ractive Drug			
		Target", Proc. Natl. Acad. Sci. 95	5:15613-15617	Lucito Diug			
T		Chan, D.C. et al., (1998) "HIV Ent	ry And Its Inhib	oition", Cell			
4		93:681-684		Ì			
		Charo, I.F. et al., (1994) "Molec	ular Cloning An	d Functional			
1 1		Expression Of Two Monocyte Chemoat	tractant Proteir	1 Receptors			
1 1		Reveals Alternative Splicing Of The Carboxyl-Terminal Tails",					
		Proc. Natl. Acad. Sci. 91:2752-2756 Chen, Z. et al., (1997) "Genetically Divergent Strains Of					
1 1		Simian Immunodeficiency Virus Use CCR5 As A Coreceptor For					
\perp		Entry", J. Virol. 71(4):2705-2714					
T - 1		Clapham, P.R. et al., (1989)	"Soluble CD4	Blocks The			
I = 1		Infectivity Of Diverse Strains Of	HIV And SIV For	T Cells And			
1 1		Monocytes But Not For Brain And Mu: 370	scle Cells", Nat	ure 337:368-			
 		<u> </u>	"Specific Ce	ell Surface			
1		Requirements For The Infection Of	CD4-Positive Ce	lls By Human			
f í		Immunodeficiency Virus Types 1 And	2 By Simian Imm	nodeficiency			
		Virus*, Virol. 181:703-715		-1			
		Co. M.S. et al., (1991) "Humanize Therapy" <i>Proc. Natl. Acad. Sci.</i> 88	ed Antibodies For :2869-2873	or Antiviral			
1		Combadiere, C. et al., (1995)	"Cloning And	Functional			
		Expression Of A Human Eosinophil Biol. Chem. 270:16941-16494		•			
1		Combadiere, C. et al., (1996) Expression Of CC CKR5, A Human Mon	"Cloning And	Functional			
1		Selective For MIP-1\alpha, MIP-1\beta, And	RANTES" . T. T.	eukoc. Riol			
		60:147-152	·	2101.			
			Change In Co-R	eceptor Use			
1 1		Correlates With Disease Progre		·1 Infected			
 		Individuals*, J. Exp. Med. 185:621		05 ====			
1 1		Cormier, E. G. et al., (2000) "Sp Amino-Terminal Domain Peptides Con	ecillo Interact	con Ut CCR5			
V		HIV-1 Envelope Glycoprotein gp120	", Proc. Natl.	Acad. Sci.			
		97-5762-5767	1				
AMINE		DATE CONSIDERED .					
GNATUR	E		2 700				
KAMINER	: Initial i	f diation considered, whether or not citation is in conformance with	MPEP 609: Draw line through	n citation if not in conformance			
not consid	ered. Inch	ude copy of this form with next communication to applicant. 'Applic here if English language Translation is attached.	cant's unique citation designat	ion number (ontional). ² Applic			

,

Form PT	0-144	9 U.S. Department of Commerce	Application Number	09/460,216		
				December 13, 1999		
			First Named Inventor	Graham P. Allaway	et al.	
INFORM	ATIO	ON DISCLOSURE CITATION		1648		
(Use severa	l sheets	if necessary)	Examiner Name	Jeffrey S. Parkin		
				50875-F-PCT		
				US/JPW/AG/LAD		
		NON PATENT LITERATURE				
Examiner (nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catal publisher, city and/or country	og, etc.) date, page(s), volu y where published.	me-issue number(s),	T²	
	•	Crowe, S.M. et al., (1992) "Hu				
\ \		Infected Monocyte-Derived Macropha				
Fuse With CD4 Lymphoid Cells In Vitro: A Possible Mechanism Of T Lymphocyte Depletion In Vivo", Clin. Immunol Immunopathol.						
		65(2):143-151	CIII. IMMUIIOI	Inunanopachoi.		
		Crump, M.P. et al., (1997) "Solut	ion Structure 1	And Basis For		
1		Functional Activity Of Strom	al-Cell Derive	d Factor-1:		
1 1		Disassociation Of CXCR4 Activation	From Binding A	nd Inhibition		
		Of HIV-1", EMBO 16:6996-7007 Cushman, M. et al., (1991) "Prepar	orion and anti t	ITI Debissibis		
-1-1		Of Aurintricarboxylic Acid Fract	iong And Anti-E	nues: Direct		
		Correlation Of Antiviral Potency	With Molecular	Weight". J.		
		Med. Chem. 34:329-337				
	Dalgleish, A.G. et al., (1984) "The CD4 (T4) Antigen Is An					
1 1		Essential Component Of The Recept	or For The AID	S Retrovirus"		
		Nature 312:763-766				
	Dalgleish, A.G., (1995) "HIV And CD26", Nat. Med. 1:881-882					
		De Rossi, A. et al., (1995) "S	ynthetic Peptio	des From The		
		Principle Neutralizing Domain Of Type 1 (HIV-1) Enhance HIV-1 Infec	Human Immunodef:	ciency Virus		
		Mechanism*, Virology 184:187-196	cton inrough A	CD4-Dependent		
1		Dean, M. et al., (1996) "Genetic R	estriction Of HI	V-1 Infection		
1 1		And Progression To AIDS By A D	eletion Allele			
		Structural Gene*, Science 273:185				
		Deen, K.C. et al., (1988) "A Solu Inhibits AIDS Virus Infection", M	ature 331:82-84			
1		Deng, X. et al., (1999) "A Synthet				
		Immunodeficiency Virus Type 1 Expression And Function Of Chemok	gp120 Downre	egulates The		
1 1		In Monocytes By Activating The	ne Receptors Co 7-Transmembran	e G-Protein-		
\		Coupled Receptor FPRL1/LXA4R*, Blo				
		Dettin, M. et al., (2003) "CCR5 N-	Terminus Peptid	es Enhance X4		
		HIV-1 Infection By CXCR4 Up-Regula	tion", Biochem.	Biophys. Res.		
- } - 		Commun. 307(3)640-646 Dimitrov, D.S. et al., (1991) "Ini	rial Character of the	771 1 5-113		
1 1		Glycoprotein-Mediated Cell Fusion	LIAL Stages UI H Nonitored By	y New yesen		
		Based On Redistribution Of Fluor				
		Retroviruses 7(10):799-805				
1 1			e CCR5 Receptor			
4		Alloantigen In CCR5A32 Homozygous		dentification		
		Of Chemokine And HIV-1 Blocking Hu Acad. Sci. 95(9):5241-5245	man Antibodies"	, Proc. Natl.		
			1			
EXAMINEI SIGNATUR		DATE CONSIDERED	7,000			
		citation considered, whether or not citation is in conformance with				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

			#: <u>}</u> _	Page 9 of 1		
Form PT	'O-144	9 U.S. Department of Commerce	Application Nunidad	09/460,216		
		Patent and Trademark Office	Filing Date	December 13, 1999		
			First Named Inventor	Graham P. Allaway et al.		
INFORM	IATIO	N DISCLOSURE CITATION	Art Unit	1648		
		if necessary)	Examiner Name	Jeffrey S. Parkin		
(OBO BOYCE)	or bilette	in necessary)		50875-F-PCT		
			Printiney Docket No.	US/JPW/AG/LAD		
		NON PATENT LITERATURE	DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), til item (book, magazine, journal, serial, symposium, catalo publisher, city and/or countr	g, etc.) date, page(s), volur	ropriate), title of the ne-issue number(s),		
		Donzella, G.A. et al., (1998)	"AMD3100, A Sm	all Molecule		
7		Inhibitor Of HIV-1 Entry Via The C 4:72-77	XCR4 Co-Receptor	r", Nat. Med.		
		Doranz, B.J. et al., (1997) "Two	Distinct CCR5	Domains Can		
1		Mediate Co-Receptor Usage By Human 1°, J. Virol. 71:6305-6314	Immunodeficiend	Cy Virus Type		
		Dragic, T. et al., (1992) "Complem	entation Of Mur	ine Cells For		
		Human Immunodeficiency Virus Enve Human/Murine Heterokaryons", J. Vi	lope/CD4-Mediat	ed Fusion In		
		Dragic, T.V. et al., (1993) "	Different Requi	rements For		
- 1 - 1		Membrane Fusion Mediated By	The Envelopes	Of Human		
		Immunodeficiency Virus Types 1 An 2359	d 2", J. Virol.	67(4):2355-		
		Dragic, T.V. et al., (1995) "Prot	einase-Resistan	t Factors In		
1 1		Human Erythrocyte Membranes Mediat	e CD-4 Dependent	Fusion With		
, i		Cells Expressing Human Immunodefic	ciency Virus Typ	e 1 Envelope		
		Glycoproteins", J. Virol. 69:1013-				
1 1		Dragic, T.V. et al., (1998) "Amin The CCR5 Coreceptor Impair (o-Terminal Subs	titutions In		
1 1		The CCR5 Coreceptor Impair of Immunodeficiency Virus Type 1 Entr	gp120 Binding			
		Dragic, T.V. et al., (2000) "A	Pinding Postert	(1):2/9-285		
		Molecule Inhibitor Of HIV-1 Entr	ornaing rocket v Within The T	Lot W 2mg11		
		Helices Of CCR5", Proc. Natl. Acad	l. Sci. 97(10):5	639-5644		
		Ebadi, M., (1998) "The Pharmacokin	etic Basis Of Th	erapeutics".		
		In CRC Desk Reference Of Clinical : Boca Raton, Pp. 1-7	Pharmacology, CF	RC Press LLC,		
1 1		Eckert, D.M. et al., (1999) "Inhib	iting HIV-1 Entr	y: Discovery		
		Of D-Peptide Inhibitors That Ta Pocket", <i>Cell</i> 99:103-115				
11		Eugene-Olsen, J. et al., (1997) "H	eterozygosity Fo	or A Deletion		
\ \ \	- 1	In The CKR-5 Gene Leads To Prolon	nged AIDS-Free	Survival And		
11		Slower CD4 T-Cell Decline In A	Cohort Of HIV-	Seropositive		
		Individuals", AIDS 11:305-310 Farzan, M. et al., (1998) "A Tyro	sine_Pich Paris	on In The M		
]	Terminus Of CCR5 Is Important For	homan Immunodeti	ciency Virus		
	ŀ	Type 1 Entry And Mediates Associati	ion Between on12	0 And CCR5*		
		J. Virol. 72:1160-1164				
		Farzan, M. et al., (1999) "Tyrosi Terminus Of CCR5 Facilitates HIV-l	ne Sulfation Of	The Amino-		
+				r i		
4	ľ	Farzan, M. et al., (2000) "A Tyrosi The N Terminus Of CCR5 Interacts Wi The HIV-1 gp 120 Envelope Glycop	th A CD4-Enhance	ed Epitope Of		
	h	Entry", J. Biol. Chem. 275:33416-3	3521			
XAMINER		DATE CONSIDERED				
IGNATUR		DATE CONSIDERED ()	12/2007			
		ditation considered, whether or not citation is in conformance with		h outstoon if not in the Committee		
nd not conside	red. Inclu	de copy of this form with next communication to applicant. 'Appli-	cant's unique citation designat	ion number (optional). Annicam		
to place a che	ockmark b	ere if English language Translation is attached.				

	A 110 D	A 85 45 32 5	001440 244			
Form PFO-144	our Department of Commerce					
	Patent and Trademark Office	Filing Date	December 13, 1999			
		First Named Inventor	Graham P. Allaway et a	ıl.		
INFORMATIO	N DISCLOSURE CITATION	Art Unit	1648			
(Use several sheets	if necessary)		Jeffrey S. Parkin			
		F	50875-F-PCT			
US/JPW/AG/LAD						
	NON PATENT LITERATURE	E DOCUMENTS				
Examiner Cite No.1	Include name of the author (in CAPITAL LETTERS), titem (book, magazine, journal, serial, symposium, catal publisher, city and/or country)	og, etc.) date, page(s), volu		T ²		
2	Feng, Y. et al., (1996) Abstr Symposium	act No. 116,21	At Keystone			
0,	Ferrer, M. et al., (1999) "Select Cell Entry Inhibitors From Biased					
	Non-Natural Binding Elements", Na Fouchier, R.A. et al., (1994) "	ture Struct. Bi	ol. 6:953-959 e Tropism Is			
	Determined At Multiple Levels Of 7 J. Clin. Invest. 94:1806-1814					
	Fouts, T.R. et al., (1997) "No Immunodeficiency Virus Type 1 Pri					
1 1	Monoclonal Antibodies Correlates	With Antibody B	inding To The			
	Oligomeric Form Of The Envelope Virol. 71:2779-2785					
Freed, E.O. et al., (1991) "Identification Of Conserved						
1 1	Residues In The Human Immunodefic Neutralizing Determinant That Ar					
	Res. Hum. Retroviruses. 7(10):807		dsion , AIDS			
	Fradd, F. and Mary, M.E. (1989) "Guide By Shearman Lehaman Hutton"	AIDS Vaccines: .				
	Frazer, J.K. and Capra, J.D. Structure And Function" Fundament	, (1999) "Imm	unoglobulins:			
	Lippincott-Raven Publishers, Phil	adelphia, Pp. 37	7-74			
=	Furuta, R.A. et al., (1998) "Captu Conformation Of HIV-1 gp41", Natus	re Struct. Biol.	5(4):276-279			
	Gauduin, M.C. et al., (1996) "Effe Of Human Immunodeficiency Viru Recombinant Immunoglobulin Molecu	s Type 1 in	Plasma By			
	Gauduin, M.C. et al., (1997) "Pass	ive Immunization	With A Human			
	Monoclonal Antibody Protects hu-PB By Primary Isolates Of HIV-1", Na	t. Med. 3:1389-1	1393			
	Ghorpade, A. et al, (1998) "Role of CCR3 And CCR5 In Human Immunodefic Of Monocytes And Microglia", J. V.	ciency Virus Typ	e 1 Infection			
	Golding, H. et al., (1992) "LFA-1 Involved In The Early Stages (Adhesion Molec	ules Are Not			
	Membrane Fusion", AIDS Res. Hum. 1	Retroviruses 8:1	593-1598			
4	Graham, B.S. et al., (1995) "Car Engl. J. Med. 333:1331-1339	ndidate AIDS Va	ccines", New			
EXAMINER SIGNATURE	DATE CONSIDERED	12/2m				
EXAMINER: Initial i	f citation considered, whether or not citation is in conformance wit	th MPEP 609: Draw line throu	gh citation if not in conformance	ce		
*EXAMINER: Initial if civition considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicate to place a checkman Natre if English language Translation is attached.						

Form PT	O-144	49 U.S. Department of Commerce	Application Number	09/460,216
		Patent and Trademark Office		December 13, 1999
			First Named Inventor	Graham P. Allaway et al.
INFORM	AATIC	ON DISCLOSURE CITATION	Art Unit	1648
		s if necessary)	Examiner Name	Jeffrey S. Parkin
•		•		50875-F-PCT
<u> </u>				US/JPW/AG/LAD
		NON PATENT LITERATURE		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catalo publisher, city and/or countr	og, etc.) date, page(s), volum	propriate), title of the me-issue number(s),
2		Grene, E. et al., (2001) "Anti-CCR		
N	l	Positive Individuals", Human Immur	nol. 62(2):143-1	.45
//		Harouse, J.M. et al., (1991) "Inh:		
	i	Neural Cell Lines By Antibodies Ag		
	L	Science, 253:320-323		
	Ī	Harrington, R.D. And Geballe,	A.P., (1993)) "Cofactor
	1	Requirement For Human Immunodefici	ency Virus Type	1 Entry Into
\longrightarrow		A CD4-Expressing Human Cell Line",	, J. Virol 67:59	39-5947
1 1	l	He, J. et al., (1997) "CCR3 And CCI Infection Of Microglia", Nature 38		ors For HIV-I
		Heath, et al., (1997) "Chemokin		77
	l .	Eosinophils. The Importance Of		
1 1	l .	Antagonistic Monoclonal Antibody",		
- 	Γ	Heidenreich, O. et al., (1995)	"Annlication (Of Antigense
		Technology To Therapeutics", Mol.	Med. Today 1:12	88-133
	i	Hildreth, J.E. et al., (1989) "	Involvement Of	A Leukocyte
	i	Adhesion Receptor (LFA-1) In HIV-1 Science 244:1075-1078	Induced Syncytiu	m Formation"
 		Hill, C.M. et al., (1998) "The Ami	no Terminus Of I	Juman CCD5 Te
1 1	i	Required For Its Function As A Rec	centor For Diver	TEP Himan And
i /		Simian Immunodeficiency Virus Envel	lope Glycoprotei	ns" Virology
	ı	248:357-371		
	•	Hirata, Y., (1989) "Characteri		-6 Receptor
		Expression By Monoclonal And Polycl 143(9):2900-2906	lonal Antibodies	", J. Immun.
		Hirsch, M.S. et al., (1997) "Antir		
		Biology, Diagnosis, Treatment, Ar	nd Prevention,	4th Edition.
		Lippincott-Raven Publishers, Phila	idelphia, Pp. 49	5-508
		Hwang, S. et al., (1991) "Identif		
		Loop As The Primary Determinant	Of Cell Tropism	a In HIV-1,
		Science 253:71-74 Jacobson, J.M. et al., (1993) "Pa	T	7 - mb -
\	ı	Treatment Of Advanced Human Immuno	Assive immunothe	erapy in The
- 1 1		J. Infect. Dis. 168:298-305	derictency Arres	infection ,
11		Jacobson, J. et al., (1999) "Resu	ults Of A Phase	Trial Of
1 1		Single-Dose PRO 542, A Novel	Inhibitor Of	HIV Entry"
1 1		Abstracts Of The 39th Interscience	Conference On A	ıntimicrobial
-	'	Agents And Chemotherapy 14		
7 1	,	Ji, H. et al., (1999) "Inhibition	n Of Human Immu	nodeficiency
₩		Virus Type 1 Infectivity By The gp	41 Core: Role Ot	A Conserved
		Hydrophobic Cavity In Membrane Fus	ion", J. viroi	/3:85/8-8586
EXAMINE		DATE CONSIDERED	1-22	
SIGNATUR	<u>(E</u>	141	12/2007	
	a	if citation considered, whether or not citation is in conformance with	A MARCA COOL Process lines about	A stanton (Suna to our Court

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark nere if English language Translation is attached.

Patent and Trademark Office First Named Inventor Gruham P. Allaway et a	Form PTO-1449	9 U.S. Department of Commerce	Application Number	09/460,216			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Art Unit 1648 Examiner Name Jeffrey S. Parkin Attorney Docket No. 50875-F-PCT US/JPW/AG/LAD NON PATENT LITERATURE DOCUMENTS Examiner Cite Include nume of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, majgazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing	 			December 13, 1999			
(Use several sheets if necessary) Examiner Name Attorney Docket No. 50875-F.PCT US/JPW/AG/LAD NON PATENT LITERATURE DOCUMENTS Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1997) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing	l		First Named Inventor	Graham P. Allaway	et al.		
NON PATENT LITERATURE DOCUMENTS Examiner Initials	INFORMATIO	ON DISCLOSURE CITATION	Art Unit	1648			
NON PATENT LITERATURE DOCUMENTS Examiner Initials' No.' Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology, 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing	(Use several sheets	s if necessary)					
NON PATENT LITERATURE DOCUMENTS Examiner Initials Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology, 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing	i		Attorney Docket No.				
Examiner Initials No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		NON PATENT LITERATURE	E DOCUMENTS	joorge viried/2/12			
Jiang, S. et al., (1993) "HIV-1 Inhibition By A Peptide", Nature 365: 113 Karwowska, S. et al., (1991) "Passive Immunization For The Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Include name of the author (in CAPITAL LETTERS), t item (book, magazine, journal, serial, symposium, catal	title of the article (when ap log, etc.) date, page(s), volu		T ²		
Treatment And Prevention Of HIV Infection", Biotech. Therap. 2:31-48 Katinger, H., (1994) "Human Monoclonal Antibodies For Passive Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing	_	Jiang, S. et al., (1993) "HIV-1	l Inhibition By	A Peptide",			
Immunotherapy Of HIV-1" Antibiot. Chemother. 46:25-37 Keller, P.M. et al., (1977) "A Fluorescence Enhancement Assay Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Treatment And Prevention Of HIV I 2:31-48	infection", Bio	tech. Therap.			
Of Cell Fusion" J. Cell Sci. 28:167-177 Kilby, J.M. et al., (1998) "Potent Suppression Of HIV-1 Replication In Humans By T-20, A Peptide Inhibitor Of gp41- Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Immunotherapy Of HIV-1" Antibiot.	Chemother. 46:	25-37			
Replication In Humans By T-20, A Peptide Inhibitor Of gp41-Mediated Virus Entry", Nat. Med. 4:1302-1307 Konigs, C. et al. (2000) "Monoclonal Antibody Screening Of Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Of Cell Fusion* J. Cell Sci. 28:1	.67-177				
Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site For HIV-1 gp120", Eur. J. Immnol. 30(4):1162-1171 Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Replication In Humans By T-20, A Mediated Virus Entry", Nat. Med.	A Peptide Inhib 4:1302-1307	itor Of gp41-			
Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against HIV-1 Infection", Chem. Pharm. Bull (Tokyo) 48(2):308-309 Koup, R.A. et al., (1996) "Defining Antibody Protection Against HIV-1 Transmission In Hu-PBL-SCID Mice", Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Phage-Displayed Random Peptide Library Reveals Mimotopes Of Chemokine Receptor CCR5: Implications For The Tertiary Structure Of The Receptor And For An N-Terminal Binding Site					
HIV-1 Transmission In Hu-PBL-SCID Mice*, Immunology. 8:263-268 Kwong P.D. et al., (1998) "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And Neutralizing		Konishi, K. et al., (2000) "Synthesis Of Peptides Mimicking Chemokine Receptor CCR5 And Their Inhibitory Effects Against					
Glycoprotein In Complex With The CD4 Receptor And Neutralizing		HIV-1 Transmission In Hu-PBL-SCID	Mice", Immunolo	gy. 8:263-268	• • • • • • • • • • • • • • • • • • • •		
Human Antibody", Nature 393:648-659		Glycoprotein In Complex With The Guman Antibody", Nature 393:648-6	CD4 Receptor And	Neutralizing			
Laal, S. et al., (1994) "Synergistic Neutralization Of Human Immunodeficiency Virus Type 1 By Combinations Of Human Monoclonal Antibodies", J. Virol 68:4001-4008		Immunodeficiency Virus Type 1 Monoclonal Antibodies, J. Virol	By Combinatio 68:4001-4008	ns Of Human			
Lacasse, R.A. et al., (1999) "Fusion-Competent Vaccines: Broad Neutralization Of Primary Isolates Of HIV", Science 283:357-362		Neutralization Of Primary Isolates	of HIV", Science	e 283:357-362			
Lee, B. et al., (1999) "Epitope Mapping Of CCR5 Reveals Multiple Conformational States And Distinct But Overlapping Structures Involved In Chemokine Coreceptor Function", J. Biol. Chem. 274:9617-9626		Multiple Conformational States A Structures Involved In Chemokine C Chem. 274:9617-9626	and Distinct But Coreceptor Functi	Overlapping on", J. Biol.			
Lehner, T. et al., (2001) "Immunogenicity Of The Extracellular Domains Of C-C Chemokine Receptor 5 And The In Vitro Effects On Simian Immunodeficiency Or HIV Infectivity", J. Immunol. 166(12):7446-7455		Domains Of C-C Chemokine Receptor Simian Immunodeficiency Or HIV 166(12):7446-7455	5 And The In Vit Infectivity*,	ro Effects On J. Immunol.			
Li, A. et al., (1997) "Synergistic Neutralization Of A Chimeric SIV/HIV Type 1 Virus With Combinations Of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies Or Hyperimmune Globulins", AIDS Res. Hum. Retroviruses 13:647-56	7	SIV/HIV Type 1 Virus With Combinat Envelope Monoclonal Antibodies Or	ions Of Human Ar	ti-HIV Type 1			
EXAMINER SIGNATURE *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance.	SIGNATURE	W	· · · · · · · · · · · · · · · · · · ·				

*EXAMINER: Initial is citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmapt here if English language Translation is attached.

		No note	لمد.				
Form Pf	O-144	9 U.S. Department of Commerce					
		Patent and Trademark Office	Filing Date	December 13, 1999			
			First Named Inventor		et al.		
INFORM	IATIO	ON DISCLOSURE CITATION	Art Unit	1648			
(Use severa	ıl sheets	if necessary)		Jeffrey S. Parkin			
				50875-F-PCT			
			I	US/JPW/AG/LAD			
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No,1	Include name of the author (in CAPITAL LETTERS), till item (book, magazine, journal, serial, symposium, catalo publisher, city and/or country	g, etc.) date, page(s), volur y where published.	ne-issue number(s),	T²		
\rightarrow		Li, A.H. et al., (1998) "Synergist Human Immunodeficiency Virus SHIV-Combination Of Human Monoclonal Antihuman Immunodeficiency Virus Virol. 72:3235-3240	Vpu+ By Triple Antibodies And	And Quadruple i High-Titer			
\		Mack, M. et al., (1998) "Aminooxy Internalization But Inhibits Rec Mechanisms Of HIV Infectivity", J.	ycling: A Nove	l Inhibitory			
		Mackay, C.R., (1996) "Chemokir Chemotaxis", J. Exp. Med 84: 799-8	ne Receptors	And T Cell			
		Maddon, P.J. et al., (1986) "The Ta Receptor And Is Expressed In The I	4 Gene Encodes T				
		Cell 47:333-348 Markosyan, R.M. et al., (2002) "Th HIV-1 Entry Env-Mediated Cell-Cell Of gp41 Ectodomain", Virology 302:	Fusion By Recor				
		Mateu, M.G. et al. (1992) "Non-Admino Acid Substitutions On Ant European J. Immunol. 22(6):1385-13	igen-Antibody F				
		Philadelphia, 1999 Pp. 11-182	pincott-Raven	Publishers,			
		Mitsuya, H. et al., (1985) Pro- Infectivity And Cytopathic Effec- Retroviruses In Human Lymphoma Leu Tokyo/VNU Science Press, Utrecht F	ct Of HTLV-III kemia Japan Sci,	In Vitro",			
		Mittler, R.S. et al. (1989) "Syne gp120-Specific Antibody In Blockin Science 245:1380-1382	rgism Between H g Human T. Cell	Activation",			
		Mohan, P. et al., (1992) "Sulfonic Of Human Immunodeficiency Virus 18:139-150	Inhibitors", An	tiviral Res.			
		Mosier, D.E., (1990) "Immunodefic Human Lymphoid Cells: New Models Immunobiology And Infectious Dis 10(4):185-191	For In-Vivo Stud	lies Of Human in. Immunol.			
		Nagasawa, T. et al., (1994) "Molect A Pre-B-Cell Growth-Stimulating F Sci. 91:2305-2309	actor*, Proc.	Natl. Acad.			
10		Nagashima, K.A. et al., (2001) "H Type 1 Entry Inhibitors PRO 5 Synergistic In Blocking Virus-Cel Infect. Dis. 183:1121-1125	42 And T-20 A	re Potently			
EXAMINE	R	DATE CONSIDERED	1 /0 410				

*EXAMINER: Initial if vitation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

		· · · · · · · · · · · · · · · · · · ·	· · · /·					
Form PT	Form PTO-1449 U.S. Department of Commerce Application Number 09/460,216							
		Patent and Trademark Office	Filing Date	December 13, 1999				
			First Named Inventor	Graham P. Allaway et al.				
INFORM	IATIO	N DISCLOSURE CITATION	Art Unit	1648				
		if necessary)	Examiner Name	Jeffrey S. Parkin				
		•	Attorney Docket No.	50875-F-PCT				
			<u> </u>	US/JPW/AG/LAD				
NON PATENT LITERATURE DOCUMENTS								
Examiner	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the							
Initials	No.	item (book, magazine, journal, serial, symposium, catalo		ne-issue number(s),				
 	,	publisher, city and/or countr Nakano, T. et al., (1995) "Vascula:		Call_Dorived				
$ \mathcal{N} $		Gla-Containing Growth-Potentiating						
$ \mathcal{X} $		Growth Factors", J. Biol. Chem. 27						
		Neote, K. et al., (1993) "Mol	ecular Cloning,	Functional				
,		Expression, And Signaling Charact	eristics Of A C	-C Chemokine				
$\vdash \vdash \vdash$		Receptor", Cell 72:415-425						
		O'Brien, W.A. et al., (1990) "HI						
		Phagocytes Can Be Determined By Re- CD4-Binding Domain*, Nature 348:69		reside of the				
		Olson, W.C. et al., (1999) "Diffe		ion Of Human				
}		Immunodeficiency Virus Type 1 Fus	ion, gp 120 Bin	ding And CC-				
		Chemokine Activity Of Monoclonal A	ntibodies To CCR	5", J. Virol.				
		73:4145-4155	2005					
	Oppermann, M. (2004) "Chemokine Receptor CCR5: Insights Into							
	Structure, Function, And Regulation", Cell. Signal. 16:1201-							
	Parren, P.W. et al., (2001) "Antibody Protects Macaques Against							
	Vaginal Challenge With A Pathogenic R5 Simian/Human							
		Immunodeficiency Virus At Seru		ng Complete				
		Neutralization <i>In Vitro" J. Virol.</i> Partidos, C. et al., (1992) "Th		iantation Of				
		Epitopes On The Immunogenicity Of						
1 1		Representing Measles Virus Prot						
		Immunology 29(5):651-658	·					
		Peden, K. et al., (1991) "Change						
		Passage In Tissue Culture Of Viru						
		Molecular Clones Of HIV-1LAI, HIV- 185:661-672	-IMML, AND HIV-I	ELL , VIFOI.				
		Poignard, P. et al., (1999) "Ne	eutralizing Ant	ibodies Have				
		Limited Effects On The Control Of						
		In Vivo", Immunity 10:431-438						
		Posner, M.R. et al., (1993) "Neutra						
		Human Monoclonal Antibody To The Cl Acq. Immune Defic. Synd. 6:7-14	De Binding Site	or abiso, or				
		Power, C.A. et al., (1995) "Molec	ular Cloning An	d Functional				
		Expression Of A Novel CC Chemokine	e Receptor cDNA	From A Human				
		Basophilic Cell Line*, J. Biol. Ci						
		Proudfoot, A.E. et al., (1996) "Ex						
		RANTES By The Retention Of The Init Potent Antagonist", J. Biol. Chem.						
		Queen, C. et al., (1989) "A Human						
		The Interleukin 2 Receptor", Proc 10033						
EXAMINE SIGNATUI		DATE CONSIDERED	12/247					
			VIVVI					

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). Applicant is to place a checkmark there if English language Translation is attached.

		· · · · · · · · · · · · · · · · · · ·	معد · المعد · ا		
Form PT	'0-14 4	9 U.S. Department of Commerce	Application Number	09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	,
İ			First Named Inventor	Graham P. Allawa	y et al.
INFORM	1ATIC	ON DISCLOSURE CITATION	Art Unit	1648	
(Use severa	al sheet	s if necessary)	Examiner Name	Jeffrey S. Parkin	
			Attorney Docket No.	50875-F-PCT	
				US/JPW/AG/LAD	
		NON PATENT LITERATURE			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catale publisher, city and/or countr	og, etc.) date, page(s), volur ry where published.	ne-issue number(s),	T ²
		Rabut, G.E. et al., (1991) "Alanir			
17 Z		Nonpolar Residues In The Amin- Differently Impair Entry Of Macrop		in Of CCR5	
		Of Human Immunodeficiency Virus Ty	pe 1", J. Virol.	72:3464-3468	
V		Raport, C.J. et al., (1996) "Mole	cular Cloning Ar	nd Functional	
,		Characterization Of A Novel Human	CC-Chemokine Red	ceptor (CCR5)	
	-	For RANTES, MIP-1β, And MIP-1α",	J.Biol. Chem. 27	1:1761-17166	
		Rodriguez, G. et al (1995) "Mediat Virus Type 1 Binding By Interact			
	•	Sulfate Proteoglycans With V3 Reg	ion Of Envelope	gp120-gp41*,	
		J. Virol. 69:2233-2239			
		Rucker, J. et al., (1996) "Regio	ns In B-Chemoki	ne Receptors	
	l	CCR5 And CCR2b That Determine HIV-87:437-446	1 Cofactor Speci	ficity", Cell	
		Ruffing, N. et al., (1998) "CCR5 H	as An Expanded L	igand-Binding	
	ı	Repertoire And Is The Primary Activated T-Cells", Cell. Immunol	Receptor Used	By MCP-2 On	
		Rudikoff, S. et al., (1982) "Sin	gle Amino Acid	Substitution	
		Altering Antigen-Binding Specific: 79:1979-1983	,		
		Rusche, J.R. et al., (1988) "Antib	odies That Inhib	oit Fusion Of	
		Human Immunodeficiency Virus-Infe Acid Sequence Of The Viral Envelop	cted Cells Bind	1 A 24-Amino	t
1 1		Sci. 85:3198-3202	e gpizo , rioc.	Naci., Acad.	I
		Sagg, M. (1997) "Clinical Spectro		unodefilency	
		Virus Diseases" AIDS: Biology,		eatment And	
		Prevention, Lippincott-Raven Public 213	shers, Philadelph	nia, Pp. 203-	ı
		Sandberg, J. and Slikker, W	I., (1995) °F	evelopmental	
		Pharmacology And Toxicology Of A	nti-HIV Therape	utic Agents:	
		Dideoxynucleosides", FASEB J. 9:11	L57-1163		
		Sandstorm, E.G. And Kaplan, J.C., AIDS: Clinical Pharmacological	(1987) *Antivira	l Therapy In	•
		Experience To Date", Drugs 34:372-	-390	Inerapeucic	
		Sato, A.I. et al., (1992) *Anti-	-CD7 Reagents I		
		Induced Syncytium Formation, " Inter			
	.	81. PA5 Poa 2017 Sato, A.I. et al., (1994) "Identii	fication Of CD7	Clyppan	
		As An Accessory Molecule In HIV-1	Mediated Syncyti	um Formation	
		And Cell Free Infection", J. Immur	101. 152:5142-51	52	
4		Sato, A.I. et al., (1995) "A Si	imple And Rapid	Method For	
. 4		Preliminary Evaluation Of In Compounds In Misch Antivir Ros	/ivo Efficacy	Of Anti-HIV	
		Compounds In Mice", Antivir. Res.	61:121-103		
EXAMINE! SIGNATUR		DATE CONSIDERED	1200		
		citation considered, whether or not citation is in conformance with	···	A cleaded to the control of	
DATE VILLAGE	!	Totalion construction, whether or not citation is in conformance with	I WILEL ORN: PLEM line month	ja ciliadon it not in confoi	rmance

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkman here if English language Translation is attached.

					.]	·-··				Page 16	<u>of 19</u>
Form PT	0-144)		U.S. D	Partm	ent of C	ommerce	Applic	rution Numb	09/460,216	
				Patent	and Tr	rademai	rk Office	Filing	Date	December 13, 1999)
								First	Named Inventor	Graham P. Allawa	v et al.
INFORM	IATIO	N DI	SCL	SURE	CITAT	rion		Art U		1648	*
(Use severa					CIIAI	1011		Evan	iner Name	Jeffrey S. Parkin	
(DSC SCVCI &	n snects	II IICC	сэлаг у	,					ney Docket No.	50875-F-PCT	
									ncy Docker 1101	US/JPW/AG/LAD	
				NON	PATEN	NT LITI	ERATURI	E DOC	CUMENTS		
Examiner Initials	Cite No. ¹	item	n (book,	magazine,	, journal, publ	serial, syn lisher, city	nposium, cuta and/or count	log, etc.) ry where	date, page(s), volu e published.	propriate), title of the me-issue number(s),	
		Trar	nsger	ic Mic	e", <i>J</i>	. Of I	mmunol.	155:	2407-2418	Of Human CD7	
		PAR, And	, A M Nucl	acroph	age-Tr Seque	copic S ence O	Strain: (Cell 1	Cropism, Vir	tion Of HIV1- rus/Cell Entry ein. <i>Research</i>	1
		Scho Ant i Glyo	ols, i-HIV copro	D. et Compo	al., (unds : Expres	(1990) Specif sed By	ically 1 T-Cell	ntera	act With The	er Olyanionic e Viral gp120 Infected With	
		Scho Poly Huma Def:	ols, yhydr an I ic. S	D. et oxycar mmunod Synd. 4	al., boxyla eficie	(1991 ates De ency V 685) "Selectrived Fiver Research Property of the	com Pheplica	nenolic Comp ation", J.		
		Inta 30:1	act F 175-1	ANTES, 87	Has 1	Potent	Anti-HI	V-1 A	ctivity", A	-68), But Not ntiviral Res.	
		Betv	ween	Human	Immun	odefic	iency Vi	rus A		ment Of Fusion d Cells Using 3-92	
·		Mole Rece	ecule eptor	3, A	Candid	date Hu	ıman Imm	ınodef		lar Adhesion rus Type 1 Co- Gen. Virol.	-{
		Scie Of 1	The H		ionale	e And l deficie	Promisin	g App	roaches To	Therapeutics: The Treatment vidual", Clin.	4
		Stei Of A 275:	inber A Rec :3607	ger, P combina 3-3607	. et a nt Hur 8	al., (2 man CC	R5-Speci	fic A	ntibody", J	racterization . Biol. Chem.	
		Hete Infe	erozy ectic	gotes n″, A	Amone IDS 1	g Lon 1:1833	g-Term -1838	Non-E	Progressors	f CCR-5 Δ32 With HIV-1	
		Dire Huma	ected an Im	l Again munode	st CX(ficien	CR4 Inlacy Vir	hibits I us Type	nfect 1 Iso	ion With Th	tibody (12G5) e Dual-Tropic 89.6 But Not 78-5683	:
	,	Su, Anti Of (<i>Bio</i>)	S.B ibodi CCR1 1. 60	et a es To Expres :658-6	1., (A C-C sion (66	1996) Chemok On Var	"Prepara tine Rece ious Typ	etion eptor, es Of	Of Specifi CCR1, And Leukocytes	ic Polyclonal Determinations J. Leukoc.	
J		Bour	nd	Anti	-LAM-1	1 ((Anti-Se	lecti	n) Anti	ment Of Cell- bodies By (18):1689-1694	4
EXAMINE SIGNATUI		1			DATE (CONSIDE	RED	12	2007		
			1						· .		

*EXAMINER: Initial if clation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

		\mathcal{L}		Page 17	of 19
Form PT	()-144	9 U.S. Department of Commerce	Application Number	09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
			First Named Inventor	Graham P. Allaway	et al.
INFORM	IATIC	ON DISCLOSURE CITATION	Art Unit	1648	
(Use severa	il sheets	s if necessary)	Examiner Name	Jeffrey S. Parkin	••.
			Attorney Docket No.	50875-F-PCT	
			<u> </u>	US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catalo			T ²
		publisher, city and/or countr	y where published.		
		Thali, M. et al., (1992) "Coo			
$\langle \rangle$		Antibodies Directed Against The Vi			
$X \mid$		The Human Immunodeficiency Virus of J. Acq. Immun. Defic. Synd. 5:591		TACODLOCETU.,	
\cup		Tilley, S. A. (1992) "Synergistic		Of HIV-1 By	
١ ١		Human Monoclonal Antibodies Again			
- 1		Binding Site gp120", AIDS Resea	rch And Human	Retroviruses	
		80:4:461-467		26	
-		Tilley, S. A. et al., (1991) "Pote Human And Chimpanzee Monoclonal			
- 1 1		Three Distinct Epitope Clusters Of			
1 1		Cent Gardes. 211-216	J		
		Travis, B.M. et al., (1992) "F			
		Hypervariable Region Of HIV-1 gpl6			
		And In The Formation Of Syncytia I. 186:313-317	n CD4-Positive C	ells", Virol.	
_		Tremblay, C.L. et al. (2000) "Stro	ong In Vitro Syn	ergy Observed	
1 1		Between The Fusion Inhibitor T-2	0 And A CXCR4	Blocker AMD-	
1 1		3100.", 7th Conference On Retr	oviruses And (Opportunistic	
		Infections Abstract 500	To 17: b C		
- 1 1		Tremblay, C.L. et al., (1999) "Str The Fusion Inhibitor T-20 And The	CXCR4 Blocker	nergy Between	
		Acq. Immun. Defici. Synd. 25(2)99-		LID 5100 , U.	
		Trkola, A. et al., (2001) "Potent,	Broad-Spectrum		
		Human Immunodeficiency Virus Type	e 1 By The CCR	5 Monoclonal	
		Antibody PRO 140", J. Virol. 75:5° Trkola, A et al (1999) "Cross-Clad		on Of Deimon	
		Isolates Of Human Immunodeficier			
		Monoclonal Antibodies And Tetra	meric CD4-IgG"	, J. Virol.	
		69:6609-6617			
		Trkola, A. et al., (1998) "Neutral	ization Sensiti	vity Of Human	
1 1		Immunodeficiency Virus Type 1 Pri And CD4-based Reagents Is Independ	mary isolates i	o Antibodies	
1 1		Virol. 72:1876-1885	ent or corecept	or usage , U.	
		Tulip, W.R. et al., (1992) "Cryst	al Structures C	f Two Mutant	
1 1		Neraminidase-Antibody Complexes Wi	ith Amino Acid S	Substitutions	
		In The Interface, J. Mol. Biol. 2 Valentin, A. et al., (1990)		te Adhesion	
		Glycoprotein CD18 Participates			
		Formation In Monocytoid And T Cell	ls", J. Immunol.	144:934-937	
		Valenzuela, A. et al., (1997) "Neu	tralizing Antib	odies Against	
		The V3 Loop Of Human Immunodefici			
1 1		CD4-Dependent And Independent Bin	aing or virus T	O CETTE, ' 1'	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'Applicant is to place a checkmark here if English language Translation is attached.

DATE CONSIDERED

Vanini, S. et al., (1992) "Discrete Regions Of HIV-1 gp41 Defined By Syncytia-Inhibiting Affinity-Purified Human

Virol. 71(11):8289-8298

EXAMINER

SIGNATURE

Antibodies", AIDS 7:167-174

		1.7	\./					
Form PT	O-144		Application Number	09/460,216				
}		Patent and Trademark Office	Filing Date	December 13, 1999				
			First Named Inventor	Graham P. Allaway et al.				
INFORM	IATIC	ON DISCLOSURE CITATION	Art Unit	1648				
(Use sever	(Use several sheets if necessary) Examiner Name Jeffrey S. Parkin							
	Attorney Docket No. 50875-F-PCT							
			<u> </u>	US/JPW/AG/LAD				
		NON PATENT LITERATURE	DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), til item (book, magazine, journal, serial, symposium, catalo publisher, city and/or countr	g, etc.) date, page(s), volum	ropriate), title of the ne-issue number(s),				
		Verrier, F.C. et al., (1997) Conformation-Dependent Epitopes O	f gp120/gp41 In	To Several hibit CCR-5-				
		Dependent Cell-To-Cell Fusion Medi	iated By The Nat	ive Envelope				
\nearrow		Glycoprotein Of A Primary Macrop Proc. Natl. Acad. Sci. 94:9326-933		-1 Isolate",				
\smile		Vijh-Warrier, S, (1996) "Synergis		ion Of William				
١. ١		Immunodeficiency Virus Type 1 E	Bv A Chimpanze	Monoclonali				
		Antibody Against The V2 Domain On	f gp120 In Comb	ination With				
		Monoclonal Antibodies Against The	V3 Loop And The	CD4-Binding				
		Site", J. Virol. 70:4466-4473						
1		Vila-Coro, A.J. et al., (2000) "1	HIV-1 Infection	Through The				
		CCR5 Receptor Is Blocked By Recepto Acad. Sci. 97(7):3388-3393	or Dimerization"	, Proc. Natl.				
		Vita, C. et al., (1999) "Rational	Engineering Of A	Miniprotein				
1		That Reproduces The Core Of The CD	4 Site Interaction	ng With HTV-1				
		Envelope Glycoprotein", Proc. Natl	l. Acad. Sci. 96	:13091-13096				
		Wang, Z.Q. et al., (1994) "Deletic	on Of T Lymphocy	tes In Human				
		CD4 Transgenic Mice Induced By H	IV-gp120 And gp	120-Specific				
		Antibodies From AIDS Patients", Eu Wanda, P.E., And Smith, J.D., (1	ır. J. Immunol.	24:1553-1557				
		Heterokaryon Detection Using Reson	.982) "A General	. Method For				
1 1		Fluorescence-Activated Cell Sorter	". J. Histochem.	& Cytochem				
		30(12):1297-1300	, o. madeoenem.	a cycochem.				
		Weinhold, K.J., et al., (1989) "	HIV-1 gp120-Med	iated Immune				
		Suppression And Lymphocyte Destruc	tion In The Abse	nce Of Viral				
- - 		Infection", J. Immunol. 142:3091-3	097					
		Wild, C. et al., (1992) "A Syntheti Immunodeficiency Virus Replicat	ic Peptide Inhibi					
]		Solution Structure And Viral Inhi	ion: Correlati	on Between				
		Sci. 89:10537-10541		mut. noau.				
		Wild, C. et al., (1993) "A Syntheti	ic Peptide From H	IIV-1 gp41 Is				
1 1		A Potent Inhibitor Of Virus Media	ted Cell-Cell F	usion", AIDS				
		Res. Hum. Retroviruses 9:1051-1053	1					
1 1		Wild, C. et al., (1994) "Peptides C	Corresponding To	A Predictive				
- 1		Alpha-Helical Domain Of Human Imm gp41 Are Potent Inhibitors Of Vir	munodericiency V	irus Type l				
		Acad. Sci. 91:9770-9774	us intection",	PLOC. Natl.				
1		Wild, C. et al., (1995) "The Inhibi	tory Activity Of	An HIV Type				
		l Peptide Correlates With Its A	bility To Inte	ract With A				
4		Leucine Zipper Structure", AIDS Res 325	s. Hum. Retrovir	uses 11:323-				
EXAMINE	~	DATE CONSIDERED						

*EXAMINER: Initial if criation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

SIGNATURE

12	20 14	M 1/2 D	1	·	
Form PI	U-14	o o partition of commerce	Application Number	09/460,216	
		Patent and Trademark Office	Filing Date	December 13, 1999	
		0.	First Named Inventor	Graham P. Allaway e	t al.
		ON DISCLOSURE CITATION	Art Unit	1648	
(Use sever	al sheet	s if necessary)	Examiner Name	Jeffrey S. Parkin	
ł				50875-F-PCT	
ļ				US/JPW/AG/LAD	
		NON PATENT LITERATURE	DOCUMENTS	·	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), ti item (book, magazine, journal, serial, symposium, catak publisher, city and/or countr	og, etc.) date, page(s), volum v where published.	ne-issue number(s),	T ²
ا ما		Wu, L. et al., (1997) "Interaction	n Of Chemokine B	eceptor CCR5	
		With Its Ligands: Multiple Domain	s For HIV-1 gp120	Binding And	
		186(8):1373-1381	Binding", J.	•	
1		Yamagami, S. et al., (1994) "c	DNA Cloning And	Functional	
		Receptor", Biochem. Biophys. Res.	Chemoattractant Commun. 212:115	6-1162	
4		Ylisastigui, L. et al., (1998)		Length And	
		Truncated RANTES Inhibit HIV- Macrophages*, AIDS 12:977-984	-1 Infection	Or Primary	
,					
	-	<u> </u>			
					<u></u>
					и <u></u>
EXAMINER		D. 67			
IGNATUR	E	DATE CONSIDERED ()	12/2007		
EXAMINER	: Initial i	citation considered, whether or not citation is in conformance with	MPEP 609: Draw line through	citation if not in conformance	œ

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmart here if English language Translation is attached.

PTO/S8/08A (04-07) Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, espond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of 29

Complete if Known					
Application Number	09/460,216				
Filing Date	December 13, 1999				
First Named Inventor	G.P. Allaway et al.				
Art Unit	1648				
Examiner Name	Jeffrey S. Parkin				
Attorney Docket Number	50875-F-PCT-US				

Examiner	Cite	Diameter 1		DOCUMENTS	
chaminer Initials*	No.	Document Number Number-Kind Code ² (F Insum)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<u> </u>		^{US-} 6,692,745	02-17-2004	Olson	
V /		^{US-} 6,797,811	09-28-2004	Gray	
		US- 5,126,433	12-21-1989	Maddon	
		^{US-} 5,021,409	06-04-1991	Murrer	
		^{US-} 5,440,021	08-05-1995	Chuntharapai	
		^{US-} 5,504,003	04-02-1996	Haodong LI	
		^{US-} 7,118,859	10-10-2006	V.M. Litwin et al.	
		^{US-} 7,138,119	11-21-2006	W.C. Olson et al.	
		^{US-} 7,060,273	06-13-2006	W.C. Olson et al.	
		^{US-} 7,122,185	10-17-2006	W.C. Olson et al.	
		^{US-} 6,908,734	06-21-2005	T. Dragic et al.	
		^{US-} 2003-0166870	12-23-2004	L. Wu et al.	
		^{US-} 2005-0118677	06-02-2005	C. Combadiere et al.	
		US- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
		US- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
$ \square$		^{US-} 2007-0026441 A1	02-01-2007	W.C. Olson et al.	
		^{US-} 11/581,944	10-16-2006	W.C. Olson et al.	
4		US- 2006-0194244	08-31-2006	G.P. Allaway et al.	

Examiner	614-	FURE	IGN PATENT DOCU	MENTS		
cxaminer Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г
A		Country Code ² "Number ⁶ "Kind Code ⁸ (If Innown)	MM-DD-YYYY	Approxime of Octobring	Or Relevant Figures Appear	۲۹
		WO 07/014114	02-01-2007			H
0		WO 94/22477	10-13-1994			Г
						
			1			

Date Signature 7017

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation; if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language This collection of information is constant to the control of the patent and the control of the patent document. This collection of information is constant to the control of the patent document. This collection of information is a control of the patent document.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any commentation the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: G.P. Allaway, et al.

Serial No.: 09/460,216 Filed: December 13, 1999

Exhibit B

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 2

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many shoots as necessary)

Complete if Known					
Application Number	09/460,216				
Filing Date	December 13, 1999				
First Named Inventor	G.P. Allaway et al.				
Art Unit	1648				
Examiner Name	Jeffrey S. Parkin	_			
Attorney Docket Number	50875-F-PCY-US				

F	000		U. S. PATEN	T DOCUMENTS	,
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (* Income)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X		US- 7,151,087 B2	12-19-2006	C. Combadiere et al.	
V		US- 2006-0233798	10-19-2006	G.P. Allaway et al.	
<u> </u>		US- 2007-0048820	03-01-2007	G.P. Allaway et al.	
		US-			
		US			
		US-			
		us-			
		U\$-			
		US-			,
		US-			
		U\$-			

		FORE	IGN PATENT DOCU	MENTS		_
Examiner Initiats*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
		Country Code ³ Number ⁴ 'Kind Code ⁵ (# known) Date MM-DD-YYYY		replicable of Crisco Doctories is	Or Relevant Figures Appear	
						Ē
						Γ
			_			

*EXAMINER: Initial (reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if hot in conformance and not considered. Include topy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sorial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

Considered

Traisation is autocred.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 3 Attorney Docket Number of 29 50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
X		PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
Ĺ		PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
		PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
		PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
		PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
		PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
		PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
		PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
*		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

-				
Examiner		Date		
Signature	i' \	Duit	1 . /	1
Signature		Considered	1 1112	1200
'EXAMINER: In	stilled if conferences considered schools are not allerton in it.			/ (w/ /

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if next in conformance and not considered. Include copyriof this form with next communication to applicant.

1 Applicant's unique challon designation number (optional). 2 Applicant is to place a check mark here if English language Translation is estached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many shoots as necessary) **Examiner Name** Jeffrey S. Parkin Sheet **Attorney Docket Number**

29

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
		PCT International Search Report Issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
Vo		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

					1
Examiner		Date			
Signature		Considered	1.6	10	2007
*EYAMINED: In	New Johnson			1,0	1 401

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique distinct designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ider the Paperwork Red	luction A	ct of 1995, no persons a	re required to respond to a collection	n of information unless it contains a valid QMB control number. Complete if Known
-				Application Number	09/460,216
			CLOSURE	Filing Date	December 13, 1999
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway
ļ	(Use as many she	eta es n	acossan/i	Art Unit	1648
				Examiner Name	Jeffrey S. Parkin
Sheet	5	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
2		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
1		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

		•
Examiner Signature Date Control Contro	ate onsidered	12/2007

EXAMINER: Initial if reference considered, whether or not criation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citagin designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Jeffrey S. Parkin

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many shoots as necessary)

Attorney Docket Number

Examiner Name

29 of

Sheet

	- T : -	NON PATENT LITERATURE DOCUMENTS	
Examiner C Initials* N			T ²
\Rightarrow		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1ß Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling Virology, 234:340-348	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used Proc. Natl. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 Is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
1	•	Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

					<u></u>
Examiner	. \	Date		\	
Cianatura	3		'	١ _	l _
Signature		Considered	1.1	しいつ	2007
EVAMINED I	tied if and the contract of th		V	1 1 2	1 000

^{*}EXAMINER: Initial if reference obnsidered, whether or not citation is in conconsidered. Include copy of the form with next communication to applicant. ered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of theorem with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	or form 1449/PTO				n of information unless it contains a valid OMB control number. Complete if Known
				Application Number	09/460,216
			SCLOSURE	Filing Date	December 13, 1999
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway
	(Use as many she	ata aa	teresenA	Art Unit	1648
(and a many and a massagy		Examiner Name	Jeffrey S. Parkin		
Sheet 7		of	29	Attorney Docket Number	50875-F-PCT-US

Examine	r Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
1		Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type Proc. Natl. Acad. Sci., 87:6574-6578	
	·	De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Proc. Natl. Acad. Sci., 89:5286-5290	
		De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Antimicrobial Agents and Chemotherapy, 38:668-674	
		De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
		Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
		Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
		Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
		Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
A		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner		Date			
Signature		Considered	١,,	1.2	2007
'EXAMINER: IT	itial if reference considered whether or not citation in in section in its			12	1001

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Stitute for form 1449PTO

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) Examiner Name Jeffrey S. Parkin Sheet 18 Attorney Docket Number 29 50875-F-PCT-US

			NON BATTENT LETTE ATURE OF COUNTY	
Exam Initial		Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\bigcirc			Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
4			Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	
			Flexner, C. and Hendrix, C. (1997). "Pharmacology", in AIDS: Biology, Diagnosis,, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		·	Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
			Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
			Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal J. Exp. Med., 181:631-640	
			Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
			Hattori, T., et al. (1989). Involvement Of Tryptase-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
			Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
A	,		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

Examiner			Date		
Signature			Considered	11/12	2827
'EXAMINER: In	itial if reference considered, whether	or not citation is in conformance with MPED an	Denvillan ibas ab		. 00

[&]quot;EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if flot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449				Complete if Known
			Application Number	09/460,216
INFORMAT		·	Filing Date	December 13, 1999
STATEMEN	IT BY A	PPLICANT	First Named Inventor	G.P. Allaway
(lise as ma	ny sheets as n	Necessary A	Art Unit	1648
1000 00 110			Examiner Name	Jeffrey S. Parkin
Sheet 9	of	29	Attorney Docket Number	50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
X		Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
<u> </u>		Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
		Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
		Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A J. Virol., 70(9):6437-6441	
		Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That is Highly Expressed in Leukocytes. J. Biol. Chem., 269:232-237	
		McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is J. Virol., 71:1692-1696	
		Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
		Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
		Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
1		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

Examiner		Date	
Cianakina	_		f \ \
Signature		Considered	14/12/2007
PEYAMINED. I	itigs if reference considered whether a set site in its in-		111/2/2001

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

Approved for use infough various vesting various vesting various. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

10

29

	 	NON PATENT LITERATURE DOCUMENTS	
Exami Initials	 Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	
0		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
1		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

				<u> </u>
Examiner \\	Date		,	
Signature	5440	. '	_	10.00
Signature	Considered	1	1 (2	12007
CYAMBER - I WILLIAM		,		100

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents. P.O. Box 1450. Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

11

29

	Lev	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	
Ĭ		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of", in AIDS: Etiology, Diagnosis,, De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For J. Enzyme Inhibit., 6:99-11	
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
1		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	_

Examiner)		Date	T			
Signature			Considered	u	100	2087)
*EXAMINER: In	itiat i retere	nce considered, whether or not citation in in confermence with MOCO co		<u> , vv</u>	}	+	

e with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include body of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiatity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/S8/08B (04-07)

50875-F-PCT-US

Approved for use through 09/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

12

29

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
)		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
4		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner	, /	Date	Ī		
0:	•	Dute	ı	I	
Signature		Considered	1	1.2	(2 <i>8</i> 3)
ATVANDATO. I		Considered		<u> </u>	00

sidered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique sigston designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

50875-F-PCT-US

Approved for use through 09/30/2007. CMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTQ **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

13

29

		NON 2 CONTRACTOR OF THE PROPERTY OF THE PROPER	
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
		August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
		March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
		December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
4		February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner		Date	
Signature		Considered	1412/2007
"EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MPEP 60	Occurring theory of a	Total Color

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		CC W 1993, NO PERSONS &	Complete if Known				
				Application Number	09/460,216			
			SCLOSURE	Fillng Date	December 13, 1999			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway			
	(Uso as many she	ante ne r	accepted	Art Unit	1648			
	1000 00 many sale		ocosomy)	Examiner Name	Jeffrey S. Parkin			
Sheet	14	of	29	Attorney Docket Number	50875-F-PCT-US			

	<u>.</u>		NON PATENT LITERATURE DOCUMENTS	
		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2		•	April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
			September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
			December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
			April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
			December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
			February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		_	May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
			October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
			July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
1	7		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

				<u> </u>
Examiner \ \		Date		
0:	į.	Date	1 1	1
Signature		Considered	1 1/1/12	12M7
*EVANIMED: Initial Medicana a ser			1 11/0	100

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include clopy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 15 **Attorney Docket Number** 29 50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
\mathcal{A}		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
•		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

				P	
Examiner ()	Date				_
Cionetius V	Date	1. 1	l	1	
Signature X	Considered	11.		1200	
"EXAMINER" Initial if reference considered whether or not state to be a second with the second state of th		100	10	12007	

on is in conformance with MPEP 609. Draw line through citation/if not in conformance and not

[&]quot;EXAMINER: Initial if before the considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attomey Docket Number

Sheet

16

29

	T 4:	NON PATENT LITERATURE DOCUMENTS	_
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
)		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
4		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

			<u> </u>
Examiner / _	Date		
Simple transfer	Date		_
Signature \	Considered	1/10	200
*EXAMINER: tritical is companied and whether an anti-station in the		$\omega \cap \nu$	1 40

red, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant is unique distinct designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet **Attorney Docket Number** 17 29 50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	***
		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

		···					.
Examiner	1		•	Date			
A	'			Date		l I	
Signature				Considered	ا ما	110	2007
					1.7	11. 4	1 200 1

EXAMINER: Initial y reference considered, whether except citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique station designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form anxion suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents. P.O. Box 1450. Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	<u> </u>	March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
\mathcal{L}		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
ļ		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
1	· · · · · · · · · · · · · · · · · · ·	April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

Examiner	1	Date				
1 ~		2000	i	1 1		
Signature		Considered	W	しょつる	しんれつ	
SEVANSIED, AND					1 -00	

EXAMINER: Initial if reference considered, whether or not distion is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copylof/bis form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is entached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete If Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin-

Attorney Docket Number

Sheet

19

29 of

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\searrow		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
9		December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
		June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
		June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
		December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
•		March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner Date Signature Considered して

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citating designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Red te for form 1449/PTO	ucuon A	Ct Ot 1995, (ID persons at	6 ledmen in leabhin in a collection	of information unless it contains a valid OMB control number. Complete if Known
Subsuit	ne toritorii 1448/.10			Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	TATEMENT BY APPLICAN			First Named Inventor	G.P. Allaway
	FORMATION DISCLOSURE Filing Date December 13, 1999 First Named Inventor Art Unit 1648 Examiner Name Jeffrey S. Parkin				
	(USB as many sne	eus as r	iecessary)	Examiner Name	Jeffrey S. Parkin
Sheet	20	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Exam	 Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\searrow		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
0		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	į
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
	!	February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
,		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

			_			
Examiner	<i>C</i> .	Date		1	l	
Signature		Considered	lic	112	2007	

EXAMINER: Initial if presence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include city of this form with next communication to applicant.

1 Applicant's unique citylin designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 21 **Attorney Docket Number** 29 of 50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
X		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
	-	May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
, L		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	

Examiner		
Examiner	Date	1 1
Signature	Considered	1.1
		16/12/2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 80	O Draw San then who	indian il not in confermente

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation is graphed in the conformation is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0651-0031

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons ar	U.S. Pater required to respond to a collection	nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it contains a valid OMB control number.
Substitute for form 1449/PTO		Complete if Known
	Application Number	09/460,216
INFORMATION DISCLOSURE	Filing Date	December 13, 1999
STATEMENT BY APPLICANT	First Named Inventor	G.P. Allaway
(Use as many sheets as necessary)	Art Unit	1648
food on menty miners as mecassary)	Examiner Name	Jeffrey S. Parkin

Attorney Docket Number

Sheet

22

29

of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
O_1		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
	_	November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
Ţ		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Examiner	11	Date		,		
C:	1		. '	\		
Signature		Considered	110	ハロ	12007	
APT 14 A A A A A A A A A A A A A A A A A A				11	\ \(\outleta\)	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation glesignation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENO FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many shoots as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 23 Attorney Docket Number 29 50875-F-PCT-US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No:1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\mathcal{L}		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	-
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
		October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
¥		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

	1				
Examiner		Date	Γ '		
Signature /	1 .	Considered	1 1	١ م.	12007
PEYALINED: Initial Want				1,0	100

[&]quot;EXAMINER: Initial if reference considered, whether or not estation is in conformance with MPEP 609. Draw tine through citation if ript in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 24 Attorney Docket Number

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
(April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902	
		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
	•	August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	
1		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	

Examiner	Date	
Cianatura /		l \ \ _
Signature /	Considered	11121200
*EYAMINED: (alticle is		11100

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique it also designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retian a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeffrey S. Parkin

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

Sheet

25

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS		
Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
\searrow		July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983		
7		August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983		
		September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983		
		December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983		
		March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983		
		September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983		
		December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545		
		July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545		
	-	June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545		
1		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	_	

			•	i e
Examiner		Date		
Signature				1
		Considered	114112	1700
'EXAMINER: In	al if reference considered, whether or not citation is in conformance with MPED co	1	74176	100

EXAMINER: Initial if inference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

26

-		NON DATENT LIERD ACTION DOCUMENT	
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
20		April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2	
		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
		May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
Ĥ		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	
4		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	

		1		
Examiner	Date			
Signature	1	• 1		_
	Considered	101	121/10)
FXAMINER: Initial if reference considered whether an initial		_,-,	<u>• - v 40</u>	,

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique titation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO				Complete if Known	
				Application Number	09/460,216	
,			SCLOSURE	Filing Date	December 13, 1999	
STATEMENT BY APPLICANT				First Named Inventor	G.P. Allaway	
	(Use as many she	ate so	teres e no A	Art Unit	1648	
·	(000 00)		roussary)	Examiner Name	Jeffrey S. Parkin	
Sheet	27	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON BATTRIT I ITED ATURE DOCUMENTS	
Examina Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
D		August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
Ĭ		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
	,	May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	
4		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	

-			
Examiner		Date	
. .	—	Date	1 1 1 -
Signature		Considuend	1 () () ()
3		Considered	I CA CZA LOO I
SEVASABIED. 1-			1 0/1 12/100/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if riet in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is estached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Substitute for form 1449/PTO **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 28 **Attorney Docket Number** 29 of 50875-F-PCT-US

-			NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.		T²
7)	October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
			September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
			March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
			September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
			February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
·			September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		•	February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
			June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
			June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	-
V	1		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797	

						.
Examiner	·		Date			
C:	. ,		Date) '	1	1
Signature	\sim		Considered	١.	100.	1244
*EYAMINED: In	241-4 27 -4	and the seal of th	Considered	10	$\mathcal{N}\mathcal{U}$	1 400)

EXAMINER: Initial if oference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if ribt in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

stitute for form 1449/PTO

Application Number

Complete if Known Substitute for form 1449/PTO **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet 29 of 29 **Attorney Docket Number** 50875-F-PCT-US

Eveniena	1 024	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
8		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797	
ď		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	
		•	

				•
Examiner	1	Date		
Signature			1 1	١
Signature ;		Considered	11112	1200
"EXAMINER: Initial	if reference considered, whether or not citation is in conformance with ME	DED 600 D	11/4/17	100

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants to place a check mark here if English language Translation is attached. This cosection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form	1449/PTO	•	Complete if Known			
			Application Number	09/460,216		
INFORM	ATION D	SCLOSURE	Filing Date	December 13, 1999	·	
			First Named Inventor	G.P. Allaway et al.		
		APPLICANT	Art Unit	1648		
(Use a	s many sheets a	s necessary)	Examiner Name	Jeffrey S. Parkin,		
eet 1	of	29	Attorney Docket Number	50875-F-PCT-US		

Sheet 1

Examiner Signature

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 6,692,745	02-17-2004	Olson	
Y		^{US-} 6,797,811	09-28-2004	Gray	
		US- 5,126,433	12-21-1989	Maddon	
		^{US-} 5,021,409	06-04-1991	Murrer	
		^{US-} 5,440,021	08-05-1995	Chuntharapai	
		^{US-} 5,504,003	04-02-1996	Haodong Li	
		US- 7,118,859	10-10-2006	V.M. Litwin et al.	
		US- 7,138,119	11-21-2006	W.C. Olson et al.	
. I		^{US-} 7,060,273	06-13-2006	W.C. Olson et al.	
		^{US-} 7,122,185	10-17-2006	W.C. Olson et al.	
		^{US-} 6,908,734	06-21-2005	T. Dragic et al.	
		^{US-} 2003-0166870	12-23-2004	L. Wu et al.	
		^{US-} 2005-0118677	06-02-2005	C. Combadiere et al.	
		US- 2007-0031408 A1	02-08-2007	W.C. Olson et al.	
		us- 2007-0020280 A1	01-25-2007	W.C. Olson et al.	
		US- 2007-0025983 A1	02-01-2007	V.M. Litwin et al.	
		^{US-} 2007-0026441 A1	02-01-2007	W.C. Olson et al.	-
		^{US-} 11/581,944	10-16-2006	W.C. Olson et al.	
•		^{US-} 2006-0194244	08-31-2006	G.P. Allaway et al.	

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
		Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Or Relevant Figures Appear	78
		WO 07/014114	02-01-2007			┢
X		WO 94/22477	10-13-1994			Т
0						
	•					

200 *EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not it conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japenese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Nond of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 it possible. *Applicant is to place a check mark here if English language Translation is attached.

Translation is statched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number 50875-F-PCT-US

Date

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date December 13, 1999 INFORMATION DISCLOSURE First Named Inventor G.P. Allaway et al. STATEMENT BY APPLICANT Art Unit 1648 (Use as many sheets as necessary) Examiner Name Jeffrey S. Parkin

Sheet 2

Signature

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (F known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
X		US- 7,151,087 B2	12-19-2006	C. Combadiere et al.	
$\bigcup_{\mathbf{L}}$		^{US-} 2006-0233798	10-19-2006	G.P. Allaway et al.	
•		US- 2007-0048820	03-01-2007	G.P. Allaway et al.	
		US-			•
		US-			
		US-	<u> </u>		
		US-			
		US-		. ,	
		US-	1		
		US-			

		FOREIG	<u>IN PATENT DOCU</u>			
	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	₹*
	<u> </u>		_			
	 					┡
	 					⊬

*EXAMINER: Initial in reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if bot in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uszto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbots as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

of 29

			NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
7		•	PCT International Preliminary Examination Report issued October 18, 1996 for International Application Publication No. WO 95/16789	
<i>U</i> ,			PCT International Preliminary Examination Report issued September 5, 1997 for International Application Publication No. WO 96/41020	
			PCT International Preliminary Examination Report issued October 16, 1999 for International Application Publication No. WO 97/47319	
		:	PCT International Preliminary Examination Report issued September 28, 2005 for International Application Publication No. WO 03/072766	
			PCT International Preliminary Examination Report issued February 15, 2001 for International Application Publication No. WO 00/35409	
			PCT International Preliminary Examination Report issued December 24, 2003 for International Application Publication No. WO 02/083172	
			PCT International Search Report issued March 13, 1995 for International Application Publication No. WO 95/16789	
			PCT International Search Report issued October 10, 1996 for International Application Publication No. WO 96/41020	
			PCT International Search Report issued June 9, 1997 for International Application Publication No. WO 97/26009	
,			PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47319	

Examiner Date Signature Considered

[&]quot;EXAMINER: Initial if reference considered, whather or not dilation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This cotection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confideratiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 08/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin **Attorney Docket Number** Sheet 50875-F-PCT-US 29 of

	// 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
X		PCT International Search Report issued September 3, 1997 for International Application Publication No. WO 97/47318	
) [PCT International Search Report issued June 7, 2000 for International Application Publication No. WO 00/35409	
		PCT International Search Report issued August 13, 2003 for International Application Publication No. WO 03/072766	
·		PCT International Search Report issued April 23, 2002 for International Application Publication No. WO 02/22077	
		PCT International Search Report issued July 31, 2003 for International Application Publication No. WO 02/083172	
		PCT International Preliminary Examination Report issued April 5, 2006 for International Application Publication No. WO 03/072766	
		PCT Written Opinion issued May 25, 2005 in connection with International Application Publication No. WO 03/072766	
		European Supplementary Search Report issued February 24, 2000 for European Patent Application No. 96921473.3	
		European Supplementary Search Report issued September 5, 2002 for European Patent Application No. 95905987.4	
J		European Supplementary Search Report issued April 27, 2006 for European Patent Application No. 01970984.9	

Examiner	<i>N</i>	Date			
Signature			idered k	12	2007

^{*}EXAMINER: Initial if eterance considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Sheet Attorney Docket Number 29 50875-F-PCT-US

	•	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Y		European Supplementary Search Report issued April 21, 2006 for European Application No. 03713632.2	
Ĭ		European Supplementary Partial Search Report issued August 26, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued November 8, 2004 for European Patent Application No. 97930120.7	
		European Supplementary Partial Search Report issued September 27, 2004 for European Application No. 99966466	
		European Patent Office Communication issued November 11, 2004 in connection with European Patent Application No. 97930120.7	i
		Genbank Sequence Report, Accession Entry X91492 for H. sapiens Chem13, submitted September 14, 1995 2005	
		Janeway and Travers (1994). Immunobiology, Current Biology Ltd., San Francisco. Pp. 10:27-10:42	
		Stryer (1988). Biochemistry, 3rd edition. Pp. 984-988	
		December 17, 2003 Third Party Observations in connection with European Application No. 97904948.3	
4		February 27, 2004 Third Party Observations in connection with European Application No. 97904948.3	

				
Examiner		Date	1	
	\\	Date	1	1
Signature		Considered	1.16	200
0.9.12.0.0		Considered	ハルム	1 000 1
SEVASABLED. I				

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include cipied this form with next communication to appacam.

1 Applicant's unique cipied designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ute for form 1449/PTO		ct or 1995, no persons a	Complete if Known			
	21010101111111111111111			Application Number	09/460,216		
INF	ORMATIO	N DIS	SCLOSURE	Filing Date	December 13, 1999		
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
	(llee ee mees et	4		Art Unit	1648		
l ·	(Use as many si	19613 83	necessary)	Examiner Name	Jeffrey S. Parkin		
Sheet	6	of	29	Attorney Docket Number	50875-F-PCT-US		

	_	NON PATENT LITERATURE DOCUMENTS	<u>-</u>
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Alkhatib, G., et al. (1996). CC CKR5: A RANTES, MIP-1a, MIP-1ß Receptor As A Fusion Cofactor For Macrophage-Tropic HIV-1. Science, 272:1955-1958	
7		Alkhatib, G., et al. (1997). HIV Co-Receptor Activity Of CCR5 And Its Inhibition By Chemokines: Independence From G Protein Signaling Virology, 234:340-348	
		Arenzana-Selsdedos, F., et al. (1996). HIV Blocked By Chemokine Antagonist. Nature, 383:400	
		Back, D.J. (1999). Pharmacological Issues Relating To Viral Resistance. Infection, 27(Suppl.2):S42-S44	
		Balzarini, et al. (1995). Suppression Of The Breakthrough Of HIV-1 In Cell Culture By Thiocarboxanilide Derivatives When Used Proc. Natl. Acad. Sci., 92:5470-5474	
		Bleul, C.C., et al. (1991). The Lymphocyte Chemoattractant SDF-1 is A Ligand For LESTR/Fusion And Blocks HIV-1 Entry. Nature, 382:829-832	•
		Brenner, T.J., et al. (1996). Relation Between HIV-1 Syncytium Inhibition Antibodies And Clinical Outcome In Children. Lancet, 337:1001-1005	
		Broder, et al. (1996). HIV And The 7-Transmembrane Domain Receptors. Pathobiology, 64(4):171-179	
		Choe, H., et al. (1996). The Beta-Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates. Cell, 85:1135-1148	
4		Cocchi, F. (1995). Identification Of RANTES, MIP-1alpha And MIP-1beta As The Major HIV-Suppressive Factors Produced By CD8+ T-Cells. Science, 270:1811-1815	

	 	1	1	į –
Examiner	Date	T		
Signature	Considered	l i	اميا	24-
	Considered	116		100

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation/designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	and of the	a or 1990, No persons a	To required to respond to a constant	n of information unless it contains a valid QMB control number. Complete if Known
				Application Number	09/460,216
INF	ORMATION	I DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many sh	note se n		Art Unit	1648
		0013 05 11	ocossary)	Examiner Name	Jeffrey S. Parkin
Sheet	7	of	29	Attorney Docket Number	50875-F-PCT-US

	•		NON DATENT LITEDATUDE DOCUMENTS	
Examiner Initials*		Cite No. ¹	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
A	X		Cruse, et al. (1995). Illustrated Dictionary Of Immunology, CRC Press, Inc, Boca Raton, FL., 143:QR180.4.C78	
1			Daar, E.S. (1990). High Concentrations Of Recombinant Soluble CD4 Are Required To Neutralize Primary Human Immunodeficiency Virus Type Proc. Natl. Acad. Sci., 87:6574-6578	
			De Clerq, et al. (1992). Potent And Selective Inhibition Of Human Immunodeficiency Virus (HIV)-1 and HIV-2 Replication By A Class Of Proc. Natl. Acad. Sci., 89:5286-5290	
			De Clerq, et al. (1994). Highly Potent And Selective Inhibition Of Human Immunodeficiency Virus By The Bicyclam Antimicrobial Agents and Chemotherapy, 38:668-674	
			De Clerq, et al. (1995). Antiviral Therapy For Human Immunodeficiency Virus Infections. J. Clin. Microbiol. Rev., 8(2):200-239	
			Deng, H., et al. (1996). Identification Of A Major Co-Receptor For Primary Isolates Of HIV-1. Nature, 381:661-666	
			Dikic (1996). Regulation of HIV-1 Infection by Chemokine Receptors. Acta. Med. Croatica, 50:163-168	
			Doranz, B.J., et al. (1996). A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin And Beta-Chemokine Receptors CKR-5, CKR-3 And CKR-2b As Fusion Cofactors. Cell, 85:1149-1158	
			Doranz, B.J., et al. (1997). A Small Molecule Inhibitor Directed Against The Chemokine Receptor CXCR4 Prevents Its Use As An HIV-1 Co-Receptor. J. Ex. Med., 186:1395-1400	
\	•		Dragic, T.V., et al. (1996). HIV-1 Entry Into CD4+Cells Is Mediated By The Chemokine Receptor CC-CKR-5. Nature, 381:667-673	

Examiner Date Signature Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicamt.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a c of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet 8

29

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
N		Fahey, J.L., et al. (1992). Status Of Immune-Based Therapies In HIV Infection And AIDS. Clin. Exp. Immunol., 88:1-5	
1		Feng, Y., et al. (1996). HIV-1 Entry Cofactor: Functional cDNA Cloning Of A Seven-Transmembrane, g Protein-Coupled Receptor. Science, 272:872-877	•
		Flexner, C. and Hendrix, C. (1997). "Pharmacology", in AIDS: Biology, Diagnosis,, 4th Edition, De Vita V., et al. eds., Lippincott-Raven Publishers. Pp. 479-493	
		Fox, J.L. (1994). No Winners Against Aids. Bio/Technology, 12:128	
		Gait, M.J and Karn, J. (1995). Progress In anti-HIV Structure Based Drug Design. TIBTECH, 13:430-438	
		Gong, J.H., et al. (1995). Antagonists Of Monocyte Chemoattractant Protein 1 Identified By Modification Of Functionally Critical NH2-Terminal J. Exp. Med., 181:631-640	-
,		Gong, J.H., et al. (1996). RANTES And MCP-3 Antagonists Bind Multiple Chemokine Receptors. J. Biol. Chem., 371:10521-10527	
		Hattori, T., et al. (1989). Involvement Of Tryptase-Related Cellular Protease(S) In Human Immunodeficiency Virus Type 1 Infection. FEBS Letters, 248:48-52	
		Haynes, B.F. (1996). Updates On The Issues Of HIV Vaccine Development. Ann. Med., 28:39-41	
ю		Howard, O.M.Z., et al. (1998). Small Molecule Inhibitor Of HIV-1 Cell Fusion Blocks Chemokine Receptor-Mediated Fusion. J. Leuk. Biol., 64:6-13	

	 					
Examiner I	'	•		Date		1
				Daic	1	1
Signature				Considered -	1 1	1000
			<u> </u>	Considered	16117	~\ 7. 9 3~ 1
PEVALENCE - LINE VI	4 and an element the second second					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if sot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway **Art Unit** 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29

Sheet

			NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2		,	Jones, S.A., et al. (1997). Chemokine Antagonists That Discriminate Between Interleukin-8 Receptors. J. Biol. Chem., 272:16166-16199	
			Klotman, et al. (1995). Transgenic Models Of HIV-1. AIDS, 9(4):313-324	
			Levy, J.A. (1996). Controlling HIV Pathogenesis: The Role Of The Non-Cytotoxic Anti-HIV Response Of CD8+ Cells. Immunology Today, 17:217-224	
			Litwin, V.M., et al. (1996). Human Immunodeficiency Virus Type 1 Membrane Fusion Mediated By A Laboratory-Adapted Strain And A J. Virol., 70(9):6437-6441	
			Loetscher, M., et al. (1994). Cloning Of A Human Seven-Transmembrane Domain Receptor, LESTR, That Is Highly Expressed In Leukocytes. J. Biol. Chem., 269:232-237	
			McKnight, A.D., et al. (1997). Inhibition Of Human Immunodeficiency Virus Fusion By A Monoclonal Antibody To A Coreceptor (CXCR4) Is J. Virol., 71:1692-1696	
			Mellors, J.W. (1996). Closing In On Human Immunodeficiency Virus-1. Nature Medicine, 2(3):274-275	
			Moser, B., et al. (1993). Interleukin-8 Antagonists Generated By N-Terminal Modification. J. Biol. Chem., 268:7125-7128	
			Oberg, B and Vrang, L. (1990). Screening for new agents. Eur. J. Clin. Microbiol. Infect. Dis., 9(7):466-471	
,	1		Oberlin, E., et al. (1996). The CXC Chemokine SDF-1 is the Ligand for LESTR/fusion and prevents infection by T-cell-line-adapted HIV-1. Nature, 382: 833-835	

					1		
Examiner	l '	\	Date				
Signature		+	Considered	Lι	112	200)
*FXAMINER: I	nerated if letter	a chneidered whether or All attetion is in conformace with MATCH CO			~~~	1000	

^{*}EXAMINER: Initial if perence considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this farm with next communication to applicant.

Applicant's unique chation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	_	ct of 1995, no persons a	Complete if Known			
•				Application Number	09/460,216		
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway		
•	(Use as many she	ote se s	occessord.	Art Unit	1648		
	(Ose as many and	O10 B0 F	·	Examiner Name	Jeffrey S. Parkin		
Sheet	10	of	29	Attorney Docket Number	50875-F-PCT-US		

, , , , , , , , , , , , , , , , , , , ,		NON DATENTA LEPRATURE DOCUMENTE	
Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
7		Oellerich, M., (1984). Enzyme-Immunoassay: A Review. J. Clin. Chem. Clin. Biochem., 22(12):895-904	•
		Proudfoot, et al. (1999). Chemokine Receptors: Future Therapeutic Targets For HIV. Biochem. Pharmacol., 57:451-463	
		Proudfoot, et al. (2000). The Strategy Of Blocking The Chemokine System To Combat Disease. Immunol. Rev., 177:246- 256	
		Raport, C.J., et al. (1996). New Members Of The Chemokine Receptor Gene Family. Journal of Leukocyte Biology, 59:18-23	
		Raport, C.J., et al. (1996). AAC50598 submitted to NCBI on April 12, 1996 (CC Chemokine Receptor 5 sequence)	
\cdot		Richman, D.D. (1996). Antiretroviral Drug-Resistance: Mechanisms, Pathogenesis, Clinical Significance. Antivir. Chemother., 4:383-395	
		Samson, M., et al. (1996). Molecular Cloning And Functional Expression Of A New Human CC-Chemokine Receptor Gene. Biochem., 35:3362-3367	
		Scarlatti, et al. (1997). In Vivo Evolution Of HIV-1 Co-Receptor Usage And Sensitivity To Chemokine-Mediated Suppression. Nature Medicine, 3(11):A2581259-1265	
		Simmons, G., et al. (1997). Potent Inhibition Of HIV-1 Infectivity In Macropages And Lymphocytes By A Novel CCR5 Antagonist. Science, 276:276-279	
1		Szabo, et al. (1992). Cd4 Changes Conformation Upon Ligand Binding. J. Immunol. 149(11):3596-3604	

Eversines		T		
Examiner	N —	Date	. \r	-1000
Signature	/ \	Considered	11 16	2 2007
25 VARABRES 1.141.4			Y	

*EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique district designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMP contact of the contact of

Substitu	te for form 1449/PTO				Complete if Known	1
				Application Number	09/460,216	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many she	ate ac c	and count	Art Unit	1648	
	1000 60 many and	1043 03 11		Examiner Name	Jeffrey S. Parkin	
Sheet	11	of	29	Attorney Docket Number	50875-F-PCT-US	フ

	-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		Trkola, A., et al. (1996). CD-4 Dependent, Antibody Sensitive Interactions Between HIV-1 And Its Co-Receptor CCR-5. Nature, 384:184-187	:
		Wells, T.N.C., et al. (1996). Selectivity And Antagonism Of Chemokine Receptors. Journal of Leukocyte Biology, 59:53-60	
		Wu, et al. (1997). CCR5 Levels And Expression Pattern Correlate With Infectability By Macrophagetropic HIV-1 In Vitro. J. Exp. Med., 185(9):1681-1691	
		Wu, L., et al. (1996). CD4-Induced Interaction Of Primary HIV-1 gpl20 Glycoproteins With The Chemokine Receptor CCR-5. Nature, 384:179-183	
		Yarchoan, et al. (1988). "Clinical Aspects Of", in AIDS: Etiology, Diagnosis,, De Vita, et al., eds., Lippincott-Raven Publishers, Philadelphia. Pp.107-109	
		Yarchoan, R. and Broder, S. (1992). Correlations Between The In Vitro And The In Vivo Activity Of Anti-HIV Agents: Implications For J. Enzyme Inhibit., 6:99-11	
		Zhang, Y.J., et al. (1994). Structure / Activity Analysis Of Human Monocyte Chemoattractant Protein-1 (MCP-1) By Mutagenesis. J. Biol. Chem., 269:15918-15924	
		February 15, 1996 Advisory Action in connection with U.S. Application Serial No. 08/169,311	
		September 13, 1995 Final Office Action in connection with U.S. Application Serial No. 08/169,311	
*		November 23, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	

<u>`</u>				
Examiner Signature	}	Date Considered	11/12	2007
ATVARABLED. A-W-114E				

[&]quot;EXAMINER: Initial if eference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include capy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Re		ct of 1995, no persons ar	re required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Jubanic	ILE TO TOTAL TARRETO			Application Number	09/460,216
INF	ORMATIO	N DIS	CLOSURE	Filing Date	December 13, 1999
STA	ATEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many si	haata aa a		Art Unit	1648
	(Use as many si	110013 43 1	ocossary)	Examiner Name	Jeffrey S. Parkin
Sheet	12	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
V	þ	August 18, 1994 Office Action in connection with U.S. Application Serial No. 08/169,311	
0		July 16, 1998 Notice of Acceptance in connection with Australian Application No. 14387/95	
		November 27, 1996 Examiner's First Report in connection with Australian Application No. 14387/95	
		July 5, 2000 Notice of Acceptance in connection with Australian Application No. 62690/96	
		November 10, 1998 Examiner's First Report in connection with Australian Application No. 62690/96	
		September 14, 2006 Official Action in connection with Canadian Application No. 2,224,003	
		September 11, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
		March 8, 2006 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
		February 24, 2005 Provision of a Copy of the Minutes in accordance with Rule 76(4) EPC in connection with European Application No. 96 921 473.3	
1		February 24, 2005 Decision to Refuse a European Patent Application in connection with European Application No. 96 921 473.3	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation tiesignatesignation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeffrey S. Parkin

50875-F-PCT-US

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number

Sheet

13

	•		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
~	Y		August 30, 2004 Summons to Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 96 921 473.3	
)	,		December 19, 2002 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
			July 6, 2001 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 96 921 473.3	
			December 20, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/973,601	
			August 3, 1999 Advisory Action in connection with U.S. Application Serial No. 08/973,601	
			March 25, 1999 Office Action in connection with U.S. Application Serial No. 08/973,601	
		1	June 24, 1998 Office Action in connection with U.S. Application Serial No. 08/973,601	
	,		January 11, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/412,284	
			December 2, 2003 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
*			February 3, 2003 Office Action in connection with U.S. Application Serial No. 09/412,284	

Examiner Signature	A		Date Considered	11	12	2887	_
*EXAMINER: In	itial if reference	considered, whether or not citation is in conformance with MDED an	O Draw line through a	dada a	- 4 (

^{*}EXAMINER: Initial if reference/considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if ribt in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique station designation number (optionals). 2 Applicant is to place a check mark here if English language Translation is extached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ite for form 1449/PTO				Complete If Known
0				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	ete pe n	ecessand	Art Unit	1648
	(oso as many sile	0.5 65 77		Examiner Name	Jeffrey S. Parkin
Sheet	14	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		April 8, 2002 Advisory Action in connection with U.S. Application Serial No. 09/412,284	
7		September 11, 2001 Final Office Action in connection with U.S. Application Serial No. 09/412,284	
		December 19, 2000 Office Action in connection with U.S. Application Serial No. 09/412,284	
		April 18, 2007 Office Action in connection with U.S. Application Serial No. 11/258,963	
		December 26, 2006 Office Action in connection with U.S. Application Serial No. 11/258,963	
		February 8, 2007 Office Action in connection with U.S. Application Serial No. 09/904,356	
		May 2, 2006 Final Office Action in connection with U.S. Application Serial No. 09/904,356	
		October 12, 2005 Office Action in connection with U.S. Application Serial No. 09/904,356	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/904,356	
1		November 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/904,356	

Examiner	1 1 1	Date			
	l '\	Duit			
Signature		Considered	1 7 1	112	200
		Considered	L VV	100	1 000
OF WARAINIFO. L.	141-160		_		

^{*}EXAMINER: Initial/fireference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if high in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation/designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information accurately a The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork R		ct of 1995, no persons a	re required to respond to a collection	n of information unless it contains a valid OMB control number. Complete if Known
Subsuit	18 101 101111 1449/P1	•		Application Number	09/460,216
INF	ORMATIO	N DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many s	shaote ac s	occessed	Art Unit	1648
	(Use as many s	2100C3 83 F	iocossary)	Examiner Name	Jeffrey S. Parkin
Sheet	15	of	29	Attorney Docket Number	50875-F-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
λ		July 1, 2003 Office Action in connection with U.S. Application Serial No. 09/904,356	
\mathcal{I}		September 29, 2003 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		January 28, 2003 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		April 9, 2002 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 14, 2001 Advisory Action in connection with U.S. Application Serial No. 09/118,415	
		November 24, 2000 Final Office Action in connection with U.S. Application Serial No. 09/118,415	
		February 11, 2000 Office Action in connection with U.S. Application Serial No. 09/118,415	
		August 3, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	
		July 17, 2006 Notice of Allowability in connection with U.S. Application Serial No. 09/891,062	
*		May 18, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/891,062	

		_			
Examiner	Date				
Signature	Considered	6	1121	200)
45144444455					_

^{*}EXAMINER: Initial if entering considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if rigt in conformance and not considered. Include cup of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandrie, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

16

29

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		August 8, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
1		March 21, 2005 Office Action in connection with U.S. Application Serial No. 09/891,062	
		May 28, 2004 Advisory Action in connection with U.S. Application Serial No. 09/891,062	
		September 24, 2003 Final Office Action in connection with U.S. Application Serial No. 09/891,062	
		December 18, 2002 Office Action in connection with U.S. Application Serial No. 09/891,062	
		April 30, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 11/544,346	,
		March 3, 1997 Office Action in connection with U.S. Application Serial No. 08/627,684	
		June 23, 1997 Office Action in connection with U.S. Application Serial No. 08/663,616	
·		March 13, 1997 Office Action in connection with U.S. Application Serial No. 08/673,682	
+		November 28, 2000 Notice of Acceptance in connection with Australian Application No. 26074/97	

Examiner Date Signature Considered

^{*}EXAMINER: Initial if leterence considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if net in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number.

	Substitute for form 1449/PTO INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Use as many sheets as necessary)			Complete if Known		
000344	io io ioiii i-tori i			Application Number	09/460,216	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	Ales on many sho			Art Unit	1648	
	(USG GS INERTY STIC	013 48 71	ocossai y)	Examiner Name	Jeffreý S. Parkin	
Sheet	17	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
\frac{1}{2}		July 13, 1999 Examiner's First Report in connection with Australian Application No. 26074/97	
		October 23, 2006 Official Action in connection with Canadian Application No. 2,250,829	
		May 27, 2005 Official Action in connection with Canadian Application No. 2,250,829	
		May 4, 2007 Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC in connection with European Application No. 97917856.3	
		January 27, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		October 21, 2005 Communication Pursuant to Article 115(2) EPC in connection with European Application No. 97917856.3	
		April 1, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		August 5, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
		January 27, 2004 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	
•		May 9, 2003 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 97917856.3	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance shd not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50875-F-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

18

Francisco	1 024-	NON PATENT LITERATURE DOCUMENTS	·
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2		March 6, 2002 Search Report Communication in connection with European Application No. 97917856.3	
1		February 27, 2007 Notification of Reasons for Rejection in connection with Japanese Application No. 535610/97	
		May 19, 2006 Examiner's First Report in connection with Australian Application No. 2004233505	
		July 26, 2004 Notice of Acceptance in connection with Australian Application No. 35106/01	
		July 5, 2004 Examiner's Second Report in connection with Australian Application No. 35106/01	
		November 1, 2002 Examiner's First Report in connection with Australian Application No. 35106/01	
		December 4, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		January 16, 2001 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/831,823	
		September 26, 2000 Advisory Action in connection with U.S. Application Serial No. 08/831,823	
Ţ		April 11, 2000 Final Office Action in connection with U.S. Application Serial No. 08/831,823	

				L
Examiner	Date		abla	
Signature	 Considered	V	112	12007
45044444		_		

[&]quot;EXAMINER: Injital if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1459.

Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1459. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	IUCIOII A	CO 1885, NO PERSONS A	e required to respond to a contector	n of information unless it contains a valid OMB control number. Complete if Known
				Application Number	09/460,216
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway
	(Use as many she	oto se s	ocaceand.	Art Unit	1648
	1030 us many and	70 LD G.3 11	ocussai y	Examiner Name	Jeffrey S. Parkin
Sheet	19	of	29	Attorney Docket Number	50875-F-PCT-US

			NON PATENT LITERATURE DOCUMENTS	
Exam		Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	X		July 21, 1999 Final Office Action in connection with U.S. Application Serial No. 08/831,823	
			December 21, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
			August 17, 1998 Office Action in connection with U.S. Application Serial No. 08/831,823	
			June 15, 2006 Final Office Action in connection with U.S. Application Serial No. 09/888,938	
			September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
			August 4, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
			May 5, 2004 Office Action in connection with U.S. Application Serial No. 09/888,938	
			June 22, 1999 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 08/876,078	
			December 21, 1998 Final Office Action in connection with U.S. Application Serial No. 08/876,078	
y			March 23, 1998 Office Action in connection with U.S. Application Serial No. 08/876,078	

Examiner		Date		~
	· _\	Dutt		.
Signature		Considered	1,1,2	2057
		Considered		<i>uu 1</i>

^{*}EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include popy of this form with next communication to applicant.

1 Applicant's unique distation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of infortation is fequired by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

29

20

	T 0:4-	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials* Cite No.1		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		June 16, 2006 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		June 17, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 98 931 261.6	
		October 17, 2006 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		February 3, 2006 Office Action in connection with U.S. Application Serial No. 09/460,216	
		July 29, 2005 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 09, 2005 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		September 26, 2003 Advisory Action in connection with U.S. Application Serial No. 09/460,216	
		February 27, 2003 Final Office Action in connection with U.S. Application Serial No. 09/460,216	
		October 2, 2001 Office Action in connection with U.S. Application Serial No. 09/460,216	
,187,40		September 9, 2002 Notice of Acceptance in connection with Australian Application No. 81426/98	

Date Examiner Considered Signature

EXAMINER: Initial if reference considered, whether of not-sitation is in conformance with MPEP 609. Draw line through distain if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information of required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO			Complete if Known		
0000000				Application Number	09/460,216	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many she	ate ae n	ecessoni	Art Unit	1648	
	(OSO US MEMY UNO	· · · · · · · · · · · · · · · · · · ·		Examiner Name	Jeffrey S. Parkin	
Sheet	21	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	•
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X		February 27, 2002 Examiner's Second Report in connection with Australian Application No. 81426/98	
Y		February 21, 2001 Examiner's First Report in connection with Australian Application No. 81426/98	
		February 4, 1997 Office Action in connection with U.S. Application Serial No. 08/665,090	
		August 29, 2000 Notice of Allowance and Allowability in connection with 08/874,618	
		November 19, 1999 Office Action in connection with U.S. Application Serial No. 08/874,618	
		May 24, 1999 Final Office Action in connection with U.S. Application Serial No. 08/874,618	
		September 2, 1998 Office Action in connection with U.S. Application Serial No. 08/874,618	
		December 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/724,105	
		March 23, 2005 Office Action in connection with U.S. Application Serial No. 09/724,105	
1		September 23, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	

					D 1	h .	
1	Examiner	,	Date				_
1	Signature		Considered	W	12	20)	
							_

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for form 1449/PTO				Complete if Known	\
9				Application Number	09/460,216	_
INF	ORMATION	I DIS	SCLOSURE	Filing Date	December 13, 1999	_
STA	ATEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many sh			Art Unit	1648	
	(USE as many sir	9943 85 1	recessary)	Examiner Name	Jeffrey S. Parkin	
Sheet	22	of	29	Attorney Docket Number	50875-F-PCT-US	7

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
nitials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
X		May 19, 2004 Office Action in connection with U.S. Application Serial No. 09/724,105	
$\sqrt{}$		December 19, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		August 8, 2006 Office Action in connection with U.S. Application Serial No. 11/400,497	
		May 29, 2001 Notice of Acceptance in connection with Australian Application No. 34026/97	
		September 28, 1999 Examiner's First Report in connection with Australian Application No. 34026/97	
		November 10, 2006 Official Action in connection with Canadian Application No. 2,257,991	
		May 23, 2005 Communications Pursuant to Article 96(2) EPC in connection with European Application No. 97 930 120.7	
		November 17, 2004 Communication of partial European search report under Rule 45 EPC in connection with European Application No. 97 930 120.7	
		September 9, 2004 Communication of partial European search report under Rule 46(1) EPC in connection with European Application No. 97 930 120.7	
4		October 17, 2006 Notification of Reasons for Rejection in connection with Japanese Application No. 501895/98 (English translation)	

Examiner	•	Date			
Signature		Considered	Lil	. 2.	200
*EXAMINER: Initiality reference	considered, whether or not citation is in conformance		otion if and	in and	

EXAMINER: Initially reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 Filing Date INFORMATION DISCLOSURE December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet

23

29

of

C	1 0:4-	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
χ		April 5, 2004 Notice of Acceptance in connection with Australian Application No. 21996/00	
<u> </u>		February 5, 2003 Examiner's First Report in connection with Australian Application No. 21996/00	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205164	
		March 29, 2006 Examiner's First Report in connection with Australian Application No. 20004205165	
		March 1, 2006 Communication under Rule 51(4) EPC in connection with European Application No. 99 966 466.7	
		January 10, 2005 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 99 966 466.7	
	1	October 14, 2004 Communication Pursuant to Article 96(1) and Rule 51(1) EPC in connection with European Application No. 99 966 466.7	
		January 18, 2007 Office communication in connection with Mexican Application No. 1006097	
		October 13, 2005 Office communication in connection with Mexican Application No. 1006097	
1		February 6, 2007 Notice of Allowability in connection with U.S. Application Serial No. 09/464,902	

Examiner Signature		Date Considered	\(02	200	—)
*EVAMINED: L	sitial in-ference annidated whather and situate is in section . It seems a					_

[,] whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 09/30/2007. OMB 0851-0031

Uni	der the Paperwork Red	uction A	ct of 1995, no persons a	U.S. Patent re required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMME of information unless it contains a valid QMB control num	RCE
	te for form 1449/PTO				Complete if Known	
				Application Number	09/460,216	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	G.P. Allaway	
	(Use as many she			Art Unit	1648	
	(Ose as many and	CIS 83 11	ocussary)	Examiner Name	Jeffrey S. Parkin	
Sheet	24	of	29	Attorney Docket Number	50875-F-PCT-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
*		January 8, 2007 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/464,902	
7		April 19, 2006 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2005 Office Action in connection with U.S. Application Serial No. 09/464,902	
		June 15, 2005 Advisory Action in connection with U.S. Application Serial No. 09/464,902	
		January 13, 2005 Final Office Action in connection with U.S. Application Serial No. 09/464,902	
·		April 2, 2004 Office Action in connection with U.S. Application Serial No. 09/464,902	
		October 21, 2003 Office Action in connection with U.S. Application Serial No. 09/464,902	
		September 25, 2001 Office Action in connection with U.S. Application Serial No. 09/464,902	
		August 7, 2006 Office Action in connection with U.S. Application Serial No. 09/594,983	
7		March 24, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/594,983	

				1		
Examiner	\	Date			~	
Signature		Considered	11.	12	200))
SEVANDIED. I						_

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique chation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This coffection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chef Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Attorney Docket Number Sheet 25 of 29 50875-F-PCT-US

				NON PATENT LITERATURE DOCUMENTS	
	Examiner Initials*		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
h			•	July 11, 2005 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
	KI			August 25, 2004 Office Action in connection with U.S. Application Serial No. 09/594,983	
	·			September 23, 2003 Notice of Allowability in connection with U.S. Application Serial No. 09/594,983	
				December 3, 2002 Final Office Action in connection with U.S. Application Serial No. 09/594,983	
				March 13, 2002 Office Action in connection with U.S. Application Serial No. 09/594,983	
				September 28, 2001 Office Action in connection with U.S. Application Serial No. 09/594,983	
				December 19, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/763,545	
				July 26, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
				June 13, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	
	1	,		February 16, 2006 Office Action in connection with U.S. Application Serial No. 10/763,545	

				I
Examiner		Date		
Signature		Considered	11/12	21200
*EYAMINED- 1	itial Enforcement agreed unbetter or not situlian in in anadomica as with HITCH on	0 0 1 1	4 4	

considered. Include copy of this form with next communication to applicant.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/088 (04-07)
Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	der the Paperwork Red ite for form 1449/PTO	luction A	ct of 1995, no persons er	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known				
Jubban	ING IOI IOIIII 1440F 10			Application Number	09/460,216			
INF	ORMATION	DIS	CLOSURE	Filing Date	December 13, 1999			
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	G.P. Allaway			
	(Use as many she	esta pa	necessal	Art Unit	1648			
	1000 to meny site		iocosai y	Examiner Name	Jeffrey S. Parkin			
Sheet	26	of	29	Attorney Docket Number	50875-F-PCT-US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	man - man and an and an and an		T ²
X		April 21, 2006 Supplementary European search report under Article 157 (2)(a) in connection with European Application No. 03 713 632.2	
7		September 7, 2005 Office Action in connection with U.S. Application Serial No. 09/888,938	
	; 	May 16, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/371,483	
		October 24, 2006 Office Action in connection with U.S. Application Serial No. 10/371,483	
		January 29, 2007 Examiner's First Report in connection Australian Application No. 2003217674	
		February 22, 2007 Communication Pursuant to Article 96(2) EPC in connection with European Application No. 03 713 632.2	
		October 12, 2004 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 03 713 632.2	
		March 14, 2006 Examination Report in connection with New Zealand Application No. 534947	
		February 21, 2003 Official Action in connection with Russian Federation Application No. 2004128252/13(030609) (English Translation)	
7		September 29, 2006 Grant of Patent in connection with Singaporean Application No. 200404610-8	

			•	
Examiner	Date			
Signature	Considered	N٢	112	12017

^{*}EXAMINER: Initial if eference considered, whether er not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include dopy of this from with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeffrey S. Parkin

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 **INFORMATION DISCLOSURE** Filing Date December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary)

Attorney Docket Number

Examiner Name

29

Sheet 27

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
X	į	August 7, 2002 Office Action in connection with U.S. Application Serial No. 09/663,219	
		January 5, 2006 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/912,824	
		January 26, 2005 Final Office Action in connection with U.S. Application Serial No. 09/912,824	
		April 20, 2004 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 2, 2003 Office Action in connection with U.S. Application Serial No. 09/912,824	
		July 3, 2006 Notice of Acceptance in connection with Australian Application No. 2001290925	
		June 28, 2005 Examiner's First Report in connection with Australian Application No. 2001290925	
		May 24, 2006 Supplementary European search report under Article 157(2) (a) EPC in connection with European Application No. 01970984.9	
		February 28, 2005 Formalities Examination in connection with European Application No. 01970984.9	
4		May 2, 2003 Communication Pursuant to Rules 109 and 110 EPC in connection with European Application No. 01970984.9	

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

50875-F-PCT-US

Approved for use through 09/30/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 09/460,216 INFORMATION DISCLOSURE Filing Date December 13, 1999 STATEMENT BY APPLICANT **First Named Inventor** G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin

Attorney Docket Number

Sheet 28 of 29

			
Examiner Cite No.1		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
N		October 25, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 09/828,615	
0		September 13, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		March 2, 2005 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 17, 2004 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		February 23, 2004 Office Action in connection with U.S. Application Serial No. 09/828,615	
		September 9, 2003 Advisory Action in connection with U.S. Application Serial No. 09/828,615	
		February 21, 2003 Final Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 25, 2002 Office Action in connection with U.S. Application Serial No. 09/828,615	
		June 9, 2005 Notice of Allowance and Allowability in connection with U.S. Application Serial No. 10/116,797	
J		April 25, 2005 Final Office Action in connection with U.S. Application Serial No. 10/116,797	

			I
Examiner	Date		
Signature /	Considered	1112	\ 2 00 7
HEVANABLED, Initial II a			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is entached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Complete if Known Substitute for form 1449/PTO **Application Number** 09/460.216 INFORMATION DISCLOSURE **Filing Date** December 13, 1999 STATEMENT BY APPLICANT First Named Inventor G.P. Allaway Art Unit 1648 (Use as many sheets as necessary) **Examiner Name** Jeffrey S. Parkin Attorney Docket Number Sheet 29 29 50875-F-PCT-US of

·			
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
X		October 6, 2004 Office Action in connection with U.S. Application Serial No. 10/116,797	
X		February 9, 2004 Office action in connection with U.S. Application Serial No. 10/116,797	
		·	

Signature Considered *EXAMINER: Initial traference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not

Date

Examiner

*EXAMINER: Initial trifference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.